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ABSTRACT 
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Small Bowel Adenocarcinoma (SBA) is a rare and aggressive neoplastic disease. 
Several aspects of SBA carcinogenesis still need to be elucidated, but risk factors and 
histomorphological similarities seem to indicate that SBA can follow a carcinogenetic 
development similar to that proposed for colorectal cancer. At molecular level, at 
odds with adenocarcinoma arising in the large intestine, very few, and fragmented, 
information is available for SBA. In general, it has been suggested that the two 
models of colorectal carcinogenesis can be valid also for SBA. For that reason, 
chemotherapies set up for the cancers of the large intestine have been applied also for 
SBA. Therefore, since recent studies led to the introduction of EGFR-targeted 
therapies in colorectal cancer, the treatment with anti-EGFR drugs can be proposed 
also for SBA patients. In particular, in colorectal cancer patients it has been 
demonstrated that KRAS mutations are correlated with the absence of efficacy of 
EGFR-targeted therapies, and it has been proposed by few studies to investigate 
additional markers of the EGFR pathway (EGFR gene copy number, BRAF and 
PIK3CA mutations, as well as PTEN protein expression), in order to increase the 
predictive power of the efficacy of anti-EGFR drugs. Information regarding these 
markers in SBA is quite completely missing. 
Primary aim of the present work was the evaluation, in the same cohort, of all the 
alterations involved in colorectal carcinogenesis, in order to shed light more deeply 
about the molecular similarity between SBA and colorectal cancer. Second aim of the 
present work was to investigate in the same cohort of SBA the aforementioned 
markers involved in the EGFR pathway, in order to verify if the pattern of these 
alterations could justify the possible introduction of these therapies also in patients 
affected by SBA.  
To do this, for the first aim we investigated β-catenin protein expression by 
immunohistochemistry (IHC), and KRAS and TP53 mutations by direct sequencing, 
as well as microsatellite instability (MSI) and allelic imbalance of Chromosome 18q 
MSI by fragment analysis on genomic DNA extracted from formalin-fixed paraffin-
embedded tissue sections. For the second aim we investigated EGFR gene status by 
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Fluorescent in situ hybridization (FISH), BRAF and PIK3CA mutational status by 
direct sequencing, as well as PTEN protein expression by IHC, in the same cohort of 
SBA.  
We recruited 40 SBA cases from the Institute of Pathology of Locarno (Canton Tessin, 
Southern Switzerland) and from three institutions of Northern Italy.  
First aim. β-catenin overexpression was observed in 23.6% at nuclear level and in 
additional 47.3% of cases only at cytoplasmic level, MSI was found in 23.6% of cases, 
KRAS mutations in 43.6% of cases, TP53 mutations in 29% of cases and allelic 
imbalance of Chromosome 18q in 75% of cases. All the percentages of alterations and 
the types of mutations are in line with those identified in the analysis of colorectal 
cancer patients. Therefore, by the analysis of all these markers in a same cohort, we 
can confirm that SBA shares the carcinogenetic development with colorectal cancer 
also at molecular level. 
Second aim. We identified a copy number gain of EGFR gene in 57.5% of cases, 
BRAF and PIK3CA mutations in 2.5% and 10.5% of cases respectively, and PTEN loss 
of expression in 25.6% of cases. Also for the EGFR pathway analysis, percentages of 
alterations and types of mutations found in SBA are in line with colorectal cancer, 
even if we did not detect the classical V600E change in the BRAF gene (where, on the 
contrary, we found a rare mutation, the G596R change). Taking into account the 
molecular algorithm proposed for the administration of EGFR-targeted therapies in 
colorectal cancer patients, if we look only at KRAS mutations, we can propose the 
administration of EGFR-targeted therapies to about 60% of patients (i.e.: KRAS wild-
type cases), and to 23% of cases if we base our evaluation on the whole EGFR 
pathway (i.e.: cases showing, at the same time, EGFR copy number gain, KRAS, 
BRAF and PIK3CA wild-type sequences, and PTEN normal expression). The 
treatment with anti-EGFR therapies of a SBA patient of our cohort who developed a 
metastatic lesion confirmed the relevance of the molecular characterization of the 
tumor to predict the response to these therapies.  
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In conclusion, our analyses of SBA confirm the feeling that the mechanisms of 
carcinogenesis of such disease are superimposable with those proposed for colorectal 
cancer. Therefore, the hypothesis that therapeutic protocols valid for the large 
intestine can be applied also to SBA patients is supported. As a consequence, the 
targeted therapies recently introduced in colorectal cancer can be proposed for SBA 
patients, pending tumor molecular characterization as demonstrated by our case 
report. 
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INTRODUCTION 
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1.1 Cancers of the small intestine   
The small intestine represents the longest part of the digestive tract, making up 75% 
of the length (about 6 m long and 4 times as long as the large intestine) and 90% of 
the absorptive surface area of the gastrointestinal tract (Figure 1.1). It has three 
sections: duodenum, jejunum and ileum (Figure 1.2). Malignant tumors of the small 
intestine are rare all over the world (Hamilton & Aaltonen, 2000), especially with 
respect to tumors arising in the other portions of the gastrointestinal tract, with a 
global incidence of less then 1.0 per 100,000 population (Curado et al, 2009). Cancers 
of the small intestine, including adenocarcinoma, carcinoid, lymphoma and sarcoma 
(the two latter are rarer than adenocarcinoma and carcinoid) account for only 0.42% 
of total cancer cases and 2.3% of cancers of digestive system in the United States 
(Jemal et al, 2009). Mortality of the cancer is even lower, accounting for only 0.2% of 
the total cancer deaths in the United States (Jemal et al, 2009).   
 
 
 
Figure 1.1: Gastrointestinal tract.  
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Approximately 30%-40% of the cancers observed in the small bowel are 
adenocarcinomas (SBA), a percentage much lower than the proportion in the colon 
where the overwhelming majority is adenocarcinomas (Haselkorn et al, 2005; 
Bilimoria et al, 2009; Schottenfeld et al, 2009). The incidence rates for SBA are 0.5-1.5 
per 100,000 in men and 0.2-1.0 per 100,000 in women. High incidence rates are 
observed in black people in several regions of the United States: more than 2 per 
100,000 men and about 1.25 per 100,000 women in the regions included in the 
Surveillance, Epidemiology and End Results (SEER) program. High rates are also 
observed in Hawaii and in New Zealand. On the contrary, the lower incidence rates 
can be found in India, Romania and in other countries of Eastern Europe (Neugut et 
al, 1998; Negri et al, 1999). From 1975 to 2000, it seems that the incidence rates are 
increased of 50% in several countries, but not in the United States (De Launoit al, 
2005). More than 50% of SBA arise in the duodenum, while ileum represents the 
rarest affected region, with the exception of patients affected by Crohn’s disease.  
Mean age of SBA occurrence is between 55 and 65 years, even if a few cases have 
been described in younger patients, especially in cases belonging to families with a 
inherited history of colorectal cancer, or with Cronh’s disease (Lashner et al, 1992). 
 
 
Figure 1.2: Small intestine. 
 11 
1.2 Risk factors 
The reason for the much lower incidence of small intestinal cancer than of colorectal 
cancer is largely unknown but has been hypothesized to be related to several 
mechanisms. The much quicker transit time of food in the small intestine than in the 
large intestine (because peristaltic ring contractions in the small intestine occur with 
greater frequency than in the colon) may result in shorter time of exposure of its 
mucosa to carcinogens. The small intestine has much lower bacterial load, thus has 
decreased concentration of potential carcinogens from bile acid breakdown (Arber et 
al, 1997). Studies also demonstrate that the small intestine generates less endogenous 
reactive oxidative species than the colon does, which may lead it to handle oxidative 
stress more effectively than the colon thus resulting in less oxidative damage during 
times of exposure to oxidant stress (Sanders et al, 2004). 
Inflammatory bowel disease includes Crohn’s disease and ulcerative colitis, two 
clinically related but histologically distinct diseases. Crohn’s disease is a recognized 
risk factor for SBA, with relative risks reported as high as 60 (Neugut et al, 1998; Pan 
et al, 2011). A meta-analysis showed a relative risk of 33.2 (95% CI: 15.9-60.9) for SBA 
in patients with Crohn’s disease (Canavan et al, 2006). Extended duration of the 
disease, distal jejunal and ileal location, male sex, small bowel bypass loops, chronic 
fistulous disease, young age of diagnosis and occupational hazards or exposure to 
halogenated aromatic compounds with aliphatic amines, asbestos and solvents are 
suggested to be associated with an increased risk of SBA in patients with Crohn’s 
disease (De Launoit al, 2005; Feldstein et al, 2008). Ulcerative colitis has been shown 
to be associated with an increased risk of colorectal cancer, hepatobiliary cancer, 
nonmelanoma skin cancer and leukemia (Winther et al, 2004; Hemminki et al, 2008). 
However, it is unclear whether patients with ulcerative colitis have an increased risk 
also for SBA (Bernstein et al, 2001; Hemminki et al, 2008).  
Celiac disease is an inflammatory small intestinal disorder characterized by the 
inability of the small intestine to deal with the gluten fractions of cereals such as 
wheat, barley and rye; its prevalence is nearly 1% of general population (Pan et al, 
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2011). The risk of SBA in patients with celiac disease is increased many-fold as 
compared with the risk in the general population (Green and Cellier, 2007) with 
reported relative risks between 60 and 80 (Green et al, 2003). SBA is most often 
located in the jejunum and is more likely to develop as an adenoma-carcinoma 
sequence than as dysplasia in flat mucosa (Green and Rampertab, 2004).  
Although the prevalence of adenomas in the small intestine is much lower than their 
prevalence in the colon, it is suggested that the adenoma-carcinoma sequence is as 
significant in the small intestine as in the large intestine (Sellner, 1990). As in the 
colon, adenoma in the small intestine appears to be a precursor of adenocarcinoma 
(Gill et al, 2001). A large fraction of villous adenomas of the small intestine has been 
shown to progress to malignancy (Bjork et al, 1990). 
Familial adenomatous polyposis (FAP) is an autosomal dominant genetic disorder 
caused by mutations of the APC gene on the long arm of chromosome 5 (Groden et 
al, 1991). Most patients diagnosed with FAP have multiple adenomas in the small 
bowel, usually in the duodenum (Bertoni et al, 1996) and these patients are at 
increased risk of SBA, especially duodenal cancer (Lepisto et al, 2009). The 
prevalence of duodenal adenomatosis in FAP patients are 50%-90% and 3%-5% of 
these patients develop duodenal cancer (Kadmon et al, 2001). 
The demonstration of a geographical correlation between rates of SBA and colorectal 
cancer (Haselkorn et al, 2005) suggests a common aetiology. Various studies have 
shown that the risk of SBA following primary colorectal cancer were elevated; in 
addition, in those diagnosed with primary SBA, there was a 4 to 5-fold risk of 
developing colorectal cancer (Murray et al, 2004; Scelo et al, 2006; Lagarde et al, 
2009). These studies suggest etiological similarities between adenocarcinomas of the 
small intestine and of the colon-rectum but, to date, potential common carcinogenic 
agents have not been elucidated in analytic epidemiological studies. Dietary factors 
have been suggested to be related to the risk of SBA. A study of SBA mortality and 
food data by WHO showed correlations with daily consumption of animal fat and 
animal protein (Lowenfels and Sonni, 1977). A case-control study of 430 SBA cases 
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and 921 controls observed two-to three-fold increases in SBA risk with frequent 
intake of red meat and salt-cured/smoked foods but no association with alcohol 
consumption (Chow et la, 1993). Another case-control study of 36 cases with SBA 
and 998 population controls also reported a significant increase in risk associated 
with frequent intake of foods rich in heterocyclic aromatic amines (based on the 
combined intake of fried bacon and ham, barbecued and/or smoked meat and 
smoked fish) in males only and with total sugar intake (Wu et al, 1997). A hospital-
based case-control study (Negri et al, 1999) found an increased risk of SBA among 
the highest consumers of red meat and of refined carbohydrates, while a decreased 
risk was associated with consumption of fish and vegetables. 
 
1.3 Clinico-pathological data 
Symptoms predicting the insurgence of SBA depend on the dimension and on the 
site of the lesion. The majority of these tumors are characterized by aspecific 
symptoms, able to be perfectly understood only when the disease is at advanced 
stage. This unlike factor leads to a late diagnosis, and as a consequence the prognosis 
is often severe. A late diagnosis of 6-8 moths is a common event for two additional 
reasons: 
- SBA can be hardly detected by the endoscope, especially when it occurs in the 
duodenum; 
- X-ray exam is not the preferred methods to identify these lesions (Dabaja et al, 
2004). 
SBA in the ileum and jejunum is characterized by abdominal pain, nausea, vomiting, 
weight loss (Schottenfeld et al, 2009). Duodenal SBA has different clinical features, 
especially due to the fact that lumen is larger than in the ileum or jejunum (Longacre 
et al, 1990).  
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1.4 Pathological features 
Duodenal SBA is typically polypoid with a necrotic central area (Figure 1.3). Very 
often an adenomatous component is still present. SBA arising near Papilla of Vater is 
usually smaller than that arising in the other regions of the small bowel, and appears 
to be a sort of nodule in the duodenum wall (Longacre et al, 1990). 
 
a b
 
Figure 1.3: Duodenal SBA with the typical polypoid aspect. 
 
SBA of the ileum or jejunum is usually identified at higher stage with respect to 
duodenal SBA, and therefore the typical appearance is represented by an infiltrative 
and ulcerated mass protruding in intestinal lumen. In the majority of cases sierosa is 
infiltrated (Bridge et al, 1975) (Figure 1.4). 
SBA occurring in patients affect by Crohn’s disease is difficult to be detected because 
of the presence of deep ulcerative lesions, generally undistinguishable from an 
inflammatory disease (Horton et al, 1994). 
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Figure 1.4: SBA with intestinal wall infiltration. a: lumen; b: sierosa. Arrows indicate 
intestinal wall infiltration  
 
At histological level, SBA (Figure 1.5) is similar to adenocarcinoma of the colon-
rectum.  
 
a b
 
Figure 1.5: Two examples of microscopical appearance of SBA. 
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1.5 Stage and grade 
Classification criteria subdivide SBA in well, moderately and poorly differentiated, 
thus identifying tumor grade. Well differentiated tumors (G1) (Figure 1.7) are 
characterized by glandular structures in more than 95% of tumor mass, moderately 
differentiated cases (G2) between 50 and 95% (Figure 1.8), poorly differentiated 
tumors (G3) by less than 50% (Figure 1.9). Undifferentiated tumors have only less 
than 5% of glandular structures (Schlemper et al, 2000). Mucinous adenocarcinoma 
are considered G3 cases. 
 
 
Figure 1.7: Well differentiated SBA (G1). 
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Figure 1.8: Moderately differentiated SBA (G2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Poorly differentiated SBA (G3). 
 
In the presence of tumor heterogeneity, that means that different components coexist 
in the same tumor, the case is classified on the basis of the higher tumor grade 
component. However, if poorly differentiated cells are present only at the invasive 
margin, this feature is not sufficient to classify the tumor as G3. 
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Tumor staging is similar to that applied for colorectal cancers. UICC classification is 
based on tumor size and infiltration (T), regional lymph nodal status (N) and 
presence of distant metastasis (M). This system, also named as TNM, was lastly 
modified in 2010 and is generally accepted. 
The tumoral lesion is considered as adenocarcinoma also in absence of muscolaris 
mucosa invasion, at odds with criteria valid for colorectal cancer, because in the 
small bowel lymphatic vessels are present very close to the epithelium, while in the 
large intestine they are localized in the muscolaris mucosa. Therefore, the possibility 
of tumoral cells to invade regional lymph nodes is higher in small bowel than in 
colon-rectum. 
 
1.6 Prognosis 
According to the data from US SEER for the period 1992 to 2005, the median 5-years 
relative survival was 28.0% for SBA in general and 32.5% for patients who 
underwent resection. This difference emphasizes the benefit of tumor resection on 
patients’ follow-up. Overall, only a minor fraction of patients can survive to SBA, 
and the cause of the severity of such a neoplastic disease can be principally ascribed 
to the delay of disease discovery (Dabaja et al, 2004). Although other cancer sites 
have demonstrated higher long-term survival rates due to novel adjuvant therapies 
over the last two decades, the US data from 1985 to 2000 showed no significant 
change in long-term survival rates for SBA (Bilimoria et al, 2009). Another study 
observed an improvement in survival rates in England, Wales and Scotland over the 
time period of 1975 to 2002 but the changes were not statistically significant because 
of the small number of patients (Shack et al, 2006). A Swedish study found 5-years 
survival rates of 39% for duodenal adenocarcinoma and 46% for jejuno-ileal 
adenocarcinoma (Zare et al, 1996). Earlier tumor stages at diagnosis (stage I and II), 
small tumor size and curative resection have been identified as factors for favorable 
overall survival, whereas poorly differentiated tumors, lymph node involvement or 
metastasis and distant metastases as factors predicting poor prognosis (Wu et al, 
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2006; Hamilton et al, 2009). However, the involvement of regional lymph nodes as 
prognostic factor is still debated, as other studies reported absence of worse survival 
for advanced cases with respect to patients with a localized disease (Willet at al, 1993; 
Agrawal et al, 2007). 
Primary relapse events in SBA patients are the loco-regional recurrence or liver 
metastasis. More rarely, peritoneal carcinomatosis can occur. Usually, relapse 
develops in the first 2 years after tumor resection (Pilati et al, 2001; Bilimoria et al, 
2009). 
 
1.7 Clinical treatment 
Primary treatment is surgery, adopted whenever possible. Duodenal lesions are 
resected on the basis of Whipple’s indications. However, due to the late diagnosis, 
very often tumors cannot be resected. A good estimation is that only 50-60% of 
patients with SBA can be radically resected (Bilimoria et al, 2009).  
Tumor relapse, due either to local recurrence or to the presence of distant metastatic 
lesions, therefore represents the main cause of death for SBA patients. As a 
consequence, major efforts have been done for the identification of the best 
chemotherapy. At the moment, however, a specific and standard protocol for the 
treatment of SBA has not been established yet. In general, oncologists prefer to apply 
the protocols set-up for cancers arising in other district of the gastrointestinal tract, 
such as for gastric and, especially, colorectal cancer.  
The use of cisplatin turned out to be quite inefficacious (Ono et al, 2008; Suenaga et 
al, 2009). On the contrary, treatments with good results in SBA patients include 
oxaliplatin or irinotecan in conjunction with 5-fluorouracil (Overman et al, 2008). In 
addition, it has been demonstrated that the combination of 5-fluoruracil, doxorubicin 
and mytomicin C is active and well tolerated in advanced cases (Gibson et al, 2005).  
However, all these combinations did not lead to a substantial benefit for SBA 
patients. Therefore, it is of particular interest the introduction of new therapeutic 
approaches for such a disease. In this category, we can easily include targeted 
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therapies, which turned out to be effective in colorectal and gastric cancer. But the 
possibility to introduce these therapies requires an extensive knowledge of the 
disease at molecular level, at least for the targets of these new compounds. 
 
1.8 Molecular data 
The data concerning the molecular characterization of SBA are few and fragmented, 
especially due to the low frequency rate of such a disease. In the majority of cases, 
only few patients are included in the analyses, and usually only few markers are 
investigated in the same cohort of cases. The most studied markers are those 
involved in colorectal carcinogenesis, i.e.: microsatellite instability, APC, KRAS, 
allelic imbalance of Chromosome 18q, and TP53. 
 
1.8.1 Microsatellite instability 
Since SBA can develop in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) 
families, a syndrome characterized by a not functioning DNA mismatch repair 
system which leads to the accumulation of errors in all over the genotype and 
especially in small regions named microsatellites, the status of microsatellite 
instability (MSI) has been investigated. The majority of studies agrees in considering 
around 10% the fraction of SBA with MSI, a percentage in keeping with what 
observed in colorectal carcinogenesis (Keller et al, 1995; Svrcek et al, 2003). Another 
study found a higher percentage of MSI (35%) (Overman et al, 2010).  
 
1.8.2 APC-β-catenin pathway 
Since SBA can occur also in FAP patients, the occurrence of APC mutations has been 
studied. The APC gene is a tumor suppressor gene encoding for a large multidomain 
protein that plays a relevant role in the wnt-signalling pathway and in intercellular 
adhesion. In the normal cells, APC is able to form a multiprotein complex with GSK-
3β and axin. This complex binds to β-catenin, which in turn is phosphorylated by 
GSK-3β and subsequently degraded by the proteasome pathway (see Figure 1.10). In 
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tumoral cells, when APC (as well as β-catenin or axin) is mutated, the multiprotein 
complex cannot be formed and, therefore, β-catenin accumulates into the cytoplasm 
and translocates into the nucleus, where activates Tcf factor, causing  transcription of 
target genes (involved in different cellular processes), such as c-myc. {4991}. In the 
literature it seems that APC mutations are a rare event in SBA carcinogenesis, at odds 
with colorectal cancer, where APC is mutated in about 80% of sporadic cases 
(Abrahams et al, 2002; Svrcek et al, 2003). 
 
 
Figure 1.10: APC/β-catenin pathway and myc overexpression in normal (left) and tumoral 
(right) cells. 
 
1.8.3 KRAS 
KRAS gene encodes for a membrane-bound 21 kd protein involved in G protein-
mediated signal transduction. KRAS protein can acquire transforming potential 
secondary to a point mutation in hot spot codons, primarily codons 12 and 13, which 
prevent the inactivation of GTP and result in continuous KRAS protein activation. In 
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SBA the percentage of KRAS mutation occurrence is superimposable with that found 
in colorectal cancer (30-40%)  (Sutter et al, 1996; Younes et al, 1997). In particular, it 
has been proposed that KRAS mutations are limited to the tumors arising in the 
duodenum, since have not been observed in tumors of ileum or jejunum (Younes et 
al, 1997). 
 
1.8.4 Allelic imbalance of Chromosome 18q 
An old study reported the loss of the long arm of Chromosome 18q in SBA (Hahn et 
al, 1996). Mapping to this chromosomal bands are three tumor suppressor genes 
mainly involved also in colorectal cancer: Deleted in Colon Cancer (DCC), SMAD4 
(previously named DPC4, as Deleted in Pancreatic Cancer locus 4) and SMAD2. The 
DCC protein plays a relevant role in the regulation of cell-cell and cell-matrix 
adhesion, while SMAD proteins are involved in cell proliferation and apoptosis. In 
SBA, the loss of this region can be observed in a wide range of cases, from 15 to 80% 
of analyzed patients (Bläker et al, 2002; Bläker et al, 2004), similarly to what observed 
in colorectal cancer. 
 
1.8.5 TP53 
The TP53 gene encodes a 393-aminoacid nuclear phosphoprotein, which negatively 
controls the cell cycle through transcriptional activation of WAF1/CIP1 gene and 
through bcl-2 and Bax binding in response to a variety of stress signals including 
DNA damage as well as hypoxia, radiation exposure, drug exposure. TP53 
mutations, especially occurring in the DNA binding domain (encoded by exons 5-8), 
represent the main mechanism of TP53 inactivation in cancer. Studies investigating 
TP53 mutations in SBA reported their detection in 20-53% of cases, a percentage in 
keeping with colorectal carcinogenesis (Lane, 1994; Abrahams et al, 2002; De Launoit 
et al, 2004).  
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1.8.6 Molecular models of colorectal carcinogenesis  
Intensive screening for genetic alterations led to the identification of two major types 
of colorectal cancer, that are distinct by their carcinogenic process (Figure 1.11). One 
is characterized by normal caryotype, normal DNA index (Houlston et al, 2001) and 
genetic instability at microsatellite loci and is called MSI-positive cancer (Ilyas et al, 
1999). The second one, valid for more than 90% of sporadic CRC and firstly proposed 
by Vogelstein’s group (Fearon and Vogelstein, 1990), suggests that APC (or, better, 
the APC-β-catenin pathway) represents the initial mutational event that determines 
hyperplastic proliferation and then early adenoma formation. The stage of late 
adenoma is achieved with KRAS mutation. Loss of tumor suppressor genes at 
chromosome 18q and mutations in TP53 gene lead to carcinoma in situ (Laurent-Puig 
et al, 1999) and then to metastasis.  
Since in SBA the percentages of alterations of these markers are similar to those 
observed in colorectal cancer, it is generally accepted that the two models proposed 
for colorectal cancers are valid also for SBA and, therefore, that SBA carcinogenesis 
mirrors that of the colon-rectum. 
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Figure 1.11: Schematic models of colorectal carcinogenesis as proposed by Vogelstein and 
colleagues 
 
 
However, these markers have not been introduced in clinical practice in the 
management of colorectal cancer patients, where, on the contrary, recent evidence 
pointed out to the relevance of the EGFR pathway. 
 
1.8.7 EGFR in colorectal cancer  
The EGFR signaling pathway is thought to play a pivotal role in tumor growth and 
progression of various cancers, including CRC. The EGFR gene encodes for a 170 kDa 
transmembrane receptor with intrinsic tyrosine kinase activity belonging to the ErbB 
family of receptor TKs [that includes ErbB1 (EGFR or HER1), ErbB2 (HER2), ErbB3, 
and ErbB4] (Figure 1.12). 
EGFR binds to, and then is activated, by several ligands, leading to receptor 
dimerization, which in turn is able to transmitting the mitogenic signaling through 
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several pathways into the nucleus by regulating several transcription factors. EGFR 
is involved in the control of the expression of genes relevant for inhibition of 
apoptosis and for tumor cell proliferation and survival, migration, adhesion and 
angiogenesis (Woodburn 1999; Arteaga, 2001; Talapatra et al, 2001; Venook, 2005). 
 
 
Figure 1.12. Structure of the EGFR protein (A), activation (B) and dimerization by ligand 
binding (C) (Mitsudomi and Yatabe, 2009). 
 
In colorectal cancer, the main mechanism of EGFR deregulation is represented by 
protein overexpression following gene amplification or at least an increase of the 
gene copy number.   
  
1.8.8 EGFR downstream cascade  
The two main pathways activated by EGFR are the RAS-RAF-MAP kinase pathway, 
mainly involved in cell proliferation, and the PI3K-PTEN-Akt pathway, mainly 
involved in cell survival and escaping from apoptosis. In these two pathways, some 
members are more deeply involved in colorectal cancer development: KRAS, BRAF, 
PI3K and PTEN (Figure 1.13). 
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Figure 1.13. Schematic representation of the two main pathways of EGFR 
downstream cascade. 
 
KRAS. See paragraph 1.8.3.  
 
BRAF. BRAF gene encodes for a RAS effector belonging to the RAF family of Ser-Thr 
kinase proteins. BRAF gene product is recruited to the plasma membrane upon 
binding to RAS-GTP, and represents a key point in the signal transduction through 
the MAP kinase pathway. The typical BRAF alteration, leading in turn in the 
constitutive activation of BRAF itself and of the MAP kinase pathway, is represented 
by point mutations, occurring in the vast majority of cases in colorectal cancer (>90%) 
at codon 600 (with the typical V600E change) (Davies et al, 2002). In colorectal cancer, 
BRAF mutations are frequently found in sporadic cases characterized by MSI, and 
are mutually exclusive with KRAS mutations (Rajagopalan et al, 2002). At the 
moment, no data concerning the involvement of BRAF in SBA cancerogenesis have 
been published. 
 
PI3K. Phosphatidylinositol 3-kinases (PI3Ks) belong to the lipid kinases family that 
regulates the signal transduction (Vivanco et al, 2002). Activation of PI3Ks results in 
the production of the second messenger phosphatidylinositol (PI) 3,4,5 trisphosphate 
(PIP3) from PI 4,5 bisphosphate (PIP2). PIP3, through AKT activation, drives various 
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downstream pathways involved in the regulation of several cellular functions 
including cellular growth, transformation, adhesion, apoptosis, survival and motility 
(Yuan et al, 2008).  
Only PI3K proteins that contain the catalytic subunit p110α and its associated 
regulatory subunit p85 (that belongs to the class IA protein) are involved in 
tumorigenesis (Samuels et al, 2004). The p110α subunit is encoded by PIK3CA, which 
in tumors is frequently iperactivated following point mutations in hot spot codons 
located in exons 9 and 20.  
In colorectal cancer, PIK3CA mutations occur in about 10-30% of cases (Samuels et al, 
2004), while their occurrence in SBA has never been investigated. 
 
PTEN. PTEN  is a tumor suppressor gene that encodes for a 403-amino acid protein 
that possesses both lipid and protein phosphatase activities. Its typical function 
consists of dephosphorylation of PIP3 and PIP2, thus preventing AKT 
phosphorylation, and maintaining it in its inactive form, thus counteracting the role 
of PI3K proteins. PTEN is therefore involved in inhibition of cell cycle progression, 
induction of cell death, modulation of arrest signal and stimulation of angiogenesis 
by influencing vascular endothelial growth factor activity and suppression of 
destabilization of hypoxia-inducible factor-1 (Sansal et al, 2004). 
In colorectal cancer PTEN is altered through mixed genetic/epigenetic mechanisms 
(intragenic mutation/epigenetic or 10q23 loss of heterozigosity (LOH)/epigenetic), 
which lead to the biallelic inactivation of the protein in 20-30% of cases. In addition to 
PTEN LOH and mutations, PTEN promoter hypermethylation is a frequent event in 
MSI sporadic colorectal cancer and may constitute an important epigenetic 
mechanism of PTEN inactivation in this setting (Goel et al, 2004). All these alterations 
lead to the loss of PTEN protein expression and can be altogether analysed by 
protein expression analyses methods such as western blot (on cells or fresh/frozen 
tissues) or immunohistochemistry (IHC) on archival fixed tissues. No data have been 
published about PTEN role in SBA. 
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Overall, mutations in KRAS, BRAF and PIK3CA genes, as well as the loss of PTEN 
protein function result in continuous activation of EGFR downstream pathways, 
regardless of whether the EGFR is activated or pharmacologically blocked.  
 
1.8.9 Targeting EGFR in colorectal cancer: anti-EGFR monoclonal antibodies 
Given the important role of EGFR and its downstream pathways in tumorigenesis 
and disease progression, this receptor has become a relevant and promising target 
for anti-cancer therapies. In vitro and in vivo studies showed that blocking EGFR and 
downstream signaling may lead to carcinoma cell growth inhibition, resulting in 
potential benefits for cancer patients. In colorectal cancer, monoclonal antibodies 
(MoAb) targeting EGFR, namely cetuximab and panitumumab, have been developed 
and introduced in clinical practice (Rocha-Lima et al, 2007; Ciardiello and Tortora, 
2008). Cetuximab, a human–mouse chimeric IgG1 MoAb, was the first EGFR-
targeted agent approved for the treatment of colorectal cancer. Panitumumab, a fully 
human IgG2 MoAb was recently approved in the US and Europe as third-line 
treatment of metastatic colorectal cancer (Jonker et al, 2007; Amado et al, 2008; 
Ciardiello and Tortora, 2008). Cetuximab and panitumumab bind to the extracellular 
domain of EGFR when it is in the inactive configuration, compete for receptor 
binding by occluding the ligand-binding region, and thereby block ligand-induced 
EGFR activation, inducing its internalization and degradation (Ciardiello and 
Tortora, 2008). Consequently, they block the activation of the EGFR mitogenic signal 
transduction pathways, and they inhibit therefore tumor cell proliferation, 
angiogenesis, invasion and metastatic spread by inducing apoptosis. Additionally, 
anti-EGFR MoAbs, particularly those of the IgG1 subclass, may recruit host immune 
functions to attack the targeted cancer cell. These functions include antibody-
dependent cellular cytotoxicity and, to a lesser extent, complement-mediated 
cytotoxicity (Kimura et al, 2007; Kurai et al, 2007). Anti-EGFR MoAbs recognize 
EGFR exclusively and are therefore highly selective for this receptor. Most studies 
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have been made using cetuximab, but same results are valid also for panitumumab. 
The ability of cetuximab for blocking the EGFR pathway is supported by preclinical 
and clinical studies. At preclinical level, it has been demonstrated that cetuximab 
alone primarily shows cytostatic activity, whereas its combination with other 
chemotherapeutic agents (such as platinum derived compounds and irinotecan) 
leads to synergistic antitumoral activity (Fan et al, 1993; Ciardiello et al, 1999; Baselga 
et al, 2000; Prewett et al, 2003). At clinical level, two phase II trials demonstrated that 
patients with advanced CRC had a response rate of 11% when cetuximab is 
administered as single agent therapy, and 23% when combined with irinotecan (Saltz 
et al, 2004; Cunningham et al, 2004; Chung et al, 2005). Both antibodies have been 
shown to reduce the risk of tumor progression and to improve overall survival (OS), 
progression-free survival (PFS) and quality of life of patients with refractory 
metastatic colorectal cancer (Saltz et al, 2004; Cunningham et al, 2004; Jonker et al, 
2007).  
 
1.8.10 Molecular mechanism of response and resistance to EGFR targeted 
monoclonal antibodies 
From early clinical studies conducted mainly in heavily pretreated chemotherapy-
refractory patients and also in chemotherapy-naïve patients with advanced colorectal 
cancer, it became clear that only 10% to 20% of patients with mCRC clinically 
benefited from anti-EGFR MoAbs (Cunningham et al, 2004; Saltz et al, 2004; Chung et 
al, 2005). This evidence, together with the side effects and the higher costs of MoAb 
therapies as compared with standard chemotherapy regimens, underlined the 
importance of studying the molecular mechanisms of primary resistance to 
cetuximab or panitumumab. 
Initially, it was hypothesized that EGFR targeted agents would be most effective in 
those tumors overexpressing the EGFR protein (Vogel et al, 2002; Arteaga, 2003). 
Preclinical studies demonstrated that anti-EGFR agents may have little activity when 
the level of EGFR expression is below a threshold level (Venook et al, 2005). 
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Consequently, cetuximab was indicated only for the treatment of patients who have 
tumors that demonstrated EGFR expression (Cunningham et al, 2004; Saltz et al, 
2004; Chung et al, 2005). However, the immunohistochemical expression of EGFR 
protein turned out to be not a reliable tool for the identification of patients to be 
treated with EGFR MoAb, due to several reasons: the type of fixative used, the 
storage time of unstained tissue sections, the type of primary antibody used and the 
methods of IHC evaluation might generate conflicting data in the EGFR assessment 
(Atkins et al, 2004; Langner et al, 2004; Kersting et al, 2006). The same was observed 
with panitumumab-treated patients (Gibson et al, 2006; Siena et al, 2007; Van et al, 
2007). 
It was next investigated whether alterations of EGFR at gene status level might be 
predictive of anti-EGFR MoAbs efficacy. Several studies showed that EGFR gene 
copy number as detected by Fluorescence In Situ Hybridization (FISH) rather than 
EGFR protein expression evaluated by IHC, might better predict cetuximab response 
in advanced colorectal cancer (Moroni et al, 2005; Lièvre et al, 2006, Frattini et al, 
2007; Sartore-Bianchi et al, 2007; Cappuzzo et al, 2008). However, a recent 
contribution demonstrated that FISH seems to be not a reproducible method to 
evaluate the EGFR gene status (Sartore-Bianchi et al, 2012). Therefore, at the moment, 
EGFR gene status is not evaluated as a marker useful for the prediction of anti-EGFR 
therapies efficacy.  
On the contrary, there is a vast consensus for the use of KRAS mutations in clinical 
setting. This type of alteration, leading to the constitutive activation of EGFR 
downstream pathways, has been clearly demonstrated to be a negative predictor of 
cetuximab/panitumumab efficacy (Siena and Bardelli, 2010). These data have been 
included in the Food and Drug Administration (FDA) of the United States, and in the 
European Medicine  Agency (EMA) guidelines. Therefore, at the moment, only 
patients with KRAS wild-type colorectal cancer can be treated with EGFR-targeted 
therapies. 
 31 
Since BRAF, PIK3CA and PTEN play a superimposable role with respect to KRAS in 
the activation of EGFR downstream pathways, it was proposed that also BRAF and 
PIK3CA mutations, as well as the loss of PTEN protein expression might identify 
patients who are resistant to anti-EGFR therapies. Although promising reports 
opened interesting perspectives confirming this assumption, thus hypothesizing the 
possibility to identify more than 70% of resistant patients when all the 
abovementioned markers were investigated simultaneously (Frattini et al, 2007; Di 
Nicolantonio et al, 2008; Sartore-Bianchi A et al., 2009) (Figure 1.14), other and more 
recent contributions did not confirmed totally these preliminary data. In particular, it 
seems that BRAF mutations play a prognostic rather than a predictive role in patients 
treated with EGFR-targeted therapies, that not all PIK3CA mutations have the same 
role (no predictive effect for exon 9 mutations, at odds with those arising in exon 20) 
and that the loss of PTEN expression should be investigated in the metastatic lesion 
rather than in the corresponding primary tumor (Loupakis F. et al., 2009; Prenen et 
al, 2009; De Roock et al, 2010; Custodio et al, 2013). For all these considerations, 
BRAF, PIK3CA and PTEN deragulations are not investigated before the 
administration of EGFR-targeted therapies. 
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Figure 1.14. Proposed algorithm for a better prediction of EGFR-targeted therapies in 
metastatic colorectal cancer patients  
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Small bowel adenocarcinoma (SBA) is a rare disease presenting high similarity (for 
histology, epidemiology and risk factors) with colorectal adenocarcinoma. At 
molecular level, however, little is known for SBA, although it has been proposed that 
SBA shares the carcinogenetic development with colorectal cancer. For that reason, 
chemotherapies set up for the cancers of the large intestine have been applied also for 
SBA.  
Primary aim of the present work was the evaluation, in the same cohort, of all the 
alterations involved in colorectal carcinogenesis, in order to shed light more deeply 
about the similarity at molecular level between SBA and colorectal cancer. To do this, 
we will evaluate MSI, β-catenin protein expression, KRAS and TP53 mutations, as 
well as allelic imbalance of Chromosome 18q. 
 
Recent studies led to the introduction of EGFR-targeted therapies in colorectal 
cancer. These new compounds showed good benefit, but only in a subgroup of 
patients. The presence of KRAS mutations was demonstrated to be correlated with 
the absence of efficacy of anti-EGFR drugs. At the same time, a few studies also 
proposed to investigate EGFR gene copy number, BRAF and PIK3CA mutations, as 
well as PTEN protein expression, in order to increase the predictive power of the 
efficacy of EGFR-targeted therapies. Second aim of the present work was therefore to 
investigate in a cohort of SBA the aforementioned markers involved in the EGFR 
pathway, in order to verify if the pattern of these alterations could justify the possible 
introduction of these therapies also in patients affected by SBA.  
 
All the proposed analyses will represent a significant improvement in the knowledge 
of the molecular characterization of SBA, which will lead to a better treatment of 
such a severe neoplastic disease. 
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PATIENTS AND METHODS 
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3.1 Patients 
We recruited 40 patients affected by SBA. Due to the low frequency of occurrence of 
this type of neoplastic disease, we collected cases from different institutions. 
- Sixteen consecutive patients were surgically resected in Canton Tessin and 
identified in the databases of the Institute of Pathology in Locarno, 
Switzerland, from 1996 to 2007. 
- Five consecutive patients were identified in the Operative Unit of Pathology, 
Civil Hospital of Legnano (Milan, Italy), from 1997 to 2005. 
- Twelve consecutive patients were identified at the Department of Medical 
Sciences, University of Eastern Piedmont “Amedeo Avogadro” of Novara 
(Italy), from 2001 to 2008. 
- Seven consecutive patients were identified in the databases of Operative Unit 
of Pathology and Laboratory Medecine of Multimedica (Milan, Italy), from 
2003 and 2009. 
Patients with tumor of Papilla of Vater were excluded. 
 
3.2 Patient treatment and clinical evaluation 
A patient of our cohort was treated with irinotecan but at the end developed a 
metastatic lesion. Therefore a treatment with cetuximab was proposed.  
The patient was treated at Oncology Institute of Southern Switzerland (Bellinzona, 
Switzerland) with cetuximab in combination with irinotecan with the following 
scheme: 
- cetuximab: loading dose of 400 mg/m2 over 2 hours, followed by weekly 250 
mg/m2 over 1 hour; 
- irinotecan: same dose and schedule used at progression. 
Treatment was continued until progressive disease (PD) or toxicity occurred, 
according to the standard criteria (Therasse et al, 2000) or to specific trial guidelines. 
Clinical response was assessed every 6 to 8 weeks with radiologic examination 
(computed tomography or magnetic resonance imaging). The Response Evaluation 
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Criteria in Solid Tumors (RECIST) (Therasse et al, 2000) were adopted for clinic 
evaluation, and objective tumor response was classified as partial response (PR), 
stable disease (SD), or PD.  
 
3.3 Molecular analyses 
All the analyses were performed on tumor specimens fixed in 10% buffered formalin 
and embedded in paraffin (FFPE). FFPE tumor blocks were reviewed for quality and 
tumor content by analyzing detailed morphology of haematoxylin and eosin stained 
tissue sections of each blocks. A single representative tumour block from each case, 
containing at least 70% of neoplastic cells, was selected for immunohistochemical, 
cytogenetic and molecular analyses. Tumour macrodissection was performed in 
tumour blocks containing less than 70% of neoplastic cells (to reduce the presence of 
non-neoplastic tissues) following Van Krieken guidelines (Van Krieken et al, 2008).  
 
3.4 Immunohistochemical analyses 
Immunohistochemical analyses were performed on 3-μm thick tissue sections using a 
Benchmark automatic immunostaining device (Ventana Medical System, Tucson, 
AZ, USA). According to manufacturer’s instructions, specimens were incubated after 
heat induced antigen retrieval with the specific antibody. More in details, tissue 
sections were sequentially deparaffinizated with xylene and rehydrated in alcohol 
solutions and then in distilled water. Subsequently, tissue sections were incubated 
for 5 minutes with proteinase K, for 5 minutes with peroxidase block solution, for 30 
minutes with primary antibody or negative control reagents and for 30 minutes with 
the secondary goat anti-mouse antibody and horseradish peroxidase molecule linked 
to a common dextran polymer. At the end, diaminobenzidine (DAB+) substrate 
chromogen solution was applied for 10 minutes and, after counterstaining with 
haematoxylin and coverslipping, the sections were kept in the dark at room 
temperature until the evaluation that was made by using a light microscope. Positive 
and negative controls were included in each slide run.  
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β-catenin. β-catenin protein expression analysis was performed using anti-β-catenin 
monoclonal antibodies (BD Biosciences, San Jose, CA, USA) at 1:50 dilution as 
previously reported (Frattini et al, 2004). A normal β-catenin expression is considered 
when tumoral tissues show a cytoplasmic staining similar to that observed in paired 
healthy mucosa. APC or β-catenin genes alterations lead to an abnormal 
accumulation of β-catenin protein in the cytoplasm, and a nuclear staining (due to 
the fact that when the β-catenin protein is too much accumulated in the cytoplasm is 
able to enter into the nucleus) can also be observed. Therefore, we considered 
negative cases those showing a cytoplasmic expression of β-catenin protein 
superimposable with β-catenin expression of healthy mucosa. Then, patients with an 
abnormally high expression of β-catenin protein were subdivided into 2 groups: 
those showing overexpression only in the cytoplasm (and named Positive-cytoplasm 
or Pos Cyt), and those showing also expression in the nucleus (and named Positive-
nucleus or Pos Nucl). Healthy tissue (i.e. normal small bowel mucosa) was used as 
internal control; colorectal adenocarcinoma with a nuclear expression of β-catenin 
was used as external positive control. 
PTEN. PTEN protein expression analysis was performed using the anti-PTEN Ab-4 
monoclonal antibodies (Neomarkers, Fremont, CA, USA) at 1:50 dilution as 
previously reported (Frattini et al, 2005; Saal et al, 2005; Frattini et al, 2007). PTEN 
staining intensity scores for invasive tumor and non-neoplastic cells were recorded 
as described in the literature (Saal et al, 2005) and on the basis of our experience 
(Frattini et al, 2007). PTEN protein expression was mainly detected at the cytoplasmic 
level, while very few cases also showed nuclear positivity. We considered PTEN 
negative tumours those showing a striong reduction or absence of immunostaining 
in at least 50% of cells, as compared with the internal control (i.e., vascular 
endothelial cells and nerves). Healthy tissue (i.e. normal colon mucosa) was used as 
internal positive control; normal endometrium was used as external positive control. 
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3.5 Fluorescent in situ hybridization (FISH) 
EGFR gene status evaluation was performed on 3-μm thick tissue sections that were 
treated using Paraffin Pretreatment kit II (Abbott Molecular, AG Baar, Switzerland) 
according to manufacturer’s instructions. Dual-colour FISH assay was performed 
using LSI EGFR/CEP7 probes (Abbott Molecular). The LSI EGFR probe is labelled in 
SpectrumOrange and covers an approximately 300 kb region that contains the entire 
EGFR gene at 7p12 (red signals). The CEP7 probe, labelled in SpectrumGreen (green 
signals), hybridises to the alpha satellite DNA located at the centromere of 
Chromosome 7 (7p11.1– q11.1) (Figure 3.1).  
 
a
7p12 LSI  EGFR
SpectrumOrang
e
7p11.1-q11.1 
CEP7 
SpectrumGreen
b
Telomero Regione 7p12 Centromero
gene EGFR
 
Figure 3.1. Visual representation of LSI EGFR/CEP7 dual colour probe; a: Probes position and 
types with respect to the entire Chromosome 7; b: Position of EGFR probe with respect to 
EGFR gene (www.abbottmolecular.com). 
 
 
Target sections and probes were co-denatured at 75°C for 5 min and allowed to 
hybridize overnight at 37°C. A post-hybridisation stringency wash was carried out in 
a water bath at 72°C for 5 min. After washing twice and drying at room temperature 
for 10 min, slides were mounted with 406-diamidino-2-phenylindole (DAPI II; Vysis). 
Fluorescent in situ hybridization signals were evaluated with a fluorescent 
automated microscope (Zeiss Axioplan 2 Imaging, Zeiss, Oberkochen, Germany) 
equipped with single and triple band pass filters. Image for documentation were 
captured using an AxioCam camera (Zeiss Axiocam MRm) and processed using the 
AxioVision system (Zeiss). Patients were classified using descriptive criteria, taking 
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into account the abnormalities revealed and the percentage of cells involved (Martin 
et al, 2009).  
To overcome the problem of tissue heterogeneity, we evaluated 10 different tumour 
areas and at least 10 representative nuclei from each area. Overall, a total of 100 cells 
for each patient were scored. For cases in which only a biopsy was available, we 
evaluated all the analysable nuclei. 
A normal cell is characterized by 2 red signals and 2 green signals (Figure 3.2a), or by 
4 red signals and 2 green signals during DNA replication (Figure 3.2b). 
 
 
Figure 3.2. Schematic representation of EGFR FISH on chromosomes and in cells. Green 
signals correspond to the centromere of Chromosome 7, red signals to EGFR gene. a: normal 
nucleus; b: normal nucleus with DNA replication. 
 
In all the other situations there is an abnormal EGFR gene status, depending on 
different mechanisms: 
1) alterations linked to the number of Chromosomes 7; 
2) alterations of EGFR gene itself; 
In the first category we can identify the following situations: 
- loss of Chromosome 7 (also named monosomy) (Figure 3.3a); 
- low polysomy (3 or 4 balanced copies of red and green signals) (Figure 3.3b); 
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- high polysomy (more than 4 balanced copies of red and green signals) (Figure 
3.3c). 
 
 
Figure 3.3. Schematic representation of EGFR alterations linked to the number of 
Chromosome 7). a: loss of Chromosome 7; b: low polysomy (for example, 3 copies of the 
Chromosome 7); c: high polysomy (more than 4 copies, in the example there are 6 copies, 
of the Chromosome 7). 
 
EGFR alterations due to a problem of EGFR gene itself are caused by gene 
amplification. In general, in this situation, the number of red signals is higher than 
that of green signals, therefore the ratio (R) between red and green signals is more 
than 2. In this category, we can identify 3 different situations, although each of them 
leads to an abnormally high number of EGFR gene:  
- low level of gene amplification (when 2<R<5) (Figure 3.4a); 
- high level of amplification HSR-type (Homogenously-Stained Regions), when 
R>5 and red signals are in clusters (Figura 3.4b); 
- high level of amplification DM-type (Double Minutes), when R>5 and red 
signals are dispersed in the nucleus and correspond to extra-chromosomal 
sequences without centromere (Figura 3.4c). 
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Figure 3.4. Schematic representation of EGFR gene amplificfation (R>2).  a: low level of 
gene amplification (R<5); b: high level of amplification HSR-type (Homogenously-
Stained Regions); c: high level of amplification DM-type (Double Minutes). 
 
On the basis of criteria published for colorectal cancer (Martin et al, 2009; Varella 
Garcia et al, 2009), cases showing only 1 Chromosome 7 were classified as EGFR 
loss. When we observed 2 Chromosomes 7 in more than 60% of cells, the tumor was 
classified as disomic. Tumour samples with an aberrant number of Chromosomes 7, 
defined as ≥ 3 copies in at least 40% of cells, were classified as polysomic and: low 
polysomic in the presence of 3 copies of Chromosomes 7, tetrasomic in the presence 
of 4 copies of Chromosomes 7, highly polysomic in the presence of more than 4 
copies of Chromosomes 7. Specimens with a R>2 between EGFR gene and 
Chromosomes 7 centromere signals in at least 10% of cells were classified as carrying 
EGFR gene amplification. As patients carrying either at least a tetrasomic profile or 
gene amplification show a significant gain of EGFR gene, we grouped them into a 
class named copy number gain (CNG), according to the criteria described in the 
literature with slight modifications (Moroni et al, 2005): this group is also considered 
to be FISH positive (FISH+). Loss of Chromosomes 7, disomy as well as low 
polysomy are cumulatively considered as FISH negative (FISH-). Table 3.1 includes 
all classifications we applied. 
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Categories Anomaly Number of cells Status 
Loss (L) 1 copy of Chromosome 7 > 50% FISH- 
Disomy (D) 2 copies of Chromosome 7 > 60% FISH- 
Low Polysomy (LP) 3 or 4 copies of Chromosome 7 > 40% 
FISH- 
FISH+(*) 
High polysomy (HP) more than 4 copies of Chromosome 7 > 40% FISH+ 
Gene Amplification (A) R>2  > 10% FISH+ 
 
Table 3.1. Interpretation criteria for EGFR FISH (Martin et al, 2009; Varella Garcia et al, 2009). 
Legend: R: ratio between gene and centromere signals (red and green signals, respectively), 
(*) only if tetrasomy. 
 
3.6 Mutational analysis by direct sequencing 
Genomic DNA was extracted using the QIAamp Mini kit (Qiagen, Chatsworth, CA, 
USA) according to manufacturer’s instructions. 
KRAS (exons 2 and 3), BRAF (exon 15), PIK3CA (exons 9 and 20) and TP53 (exons 4-
10) gene mutations were detected by direct sequencing on genomic DNA as already 
reported (Frattini et al, 2004; Frattini et al, 2005; Di Nicolantonio et al, 2008). KRAS 
exon 2 includes codons 12 and 13, KRAS exon 3 includes codon 61, BRAF exon 15 
includes codon 600, PIK3CA exon 9 includes codons 542 and 545 and PIK3CA exon 
20 includes codon 1047. All these codons represent sites where the large majority of 
oncogenic mutations occur (Davies et al, 2002; Frattini et al, 2004; Samuels et al, 
2004). As for TP53 gene, there are not specific hotspots (although a higher 
percentage of alterations is observed in codons 175, 245, 248 and 273), and the 
mutations can occur in all the nucleotides between exon 4 and exon 10: therefore we 
amplified all these exons. The nucleotide sequence corresponding to every exon was 
amplified from tumour-extracted genomic DNA by Polimerase Chain Reaction 
(PCR), purified (Microcon YM-50, Millipore, Billerica, MA, USA) and directly 
sequenced. The list of primers used for mutational analyses is reported in Table 3.2. 
All samples were subjected to automated sequencing by ABI PRISM 3130 (Applied 
Biosystems, Foster City, CA, USA). All mutated cases were confirmed at least twice 
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starting from independent PCR reactions. In each case, the detected mutation was 
confirmed in the sequence as sense and antisense strands.  
 
Gene Exon Forward Primer Reverse Primer Annealing  
Temperature (°C) 
K-Ras 2 5’-TGGTGGAGTATTTGATAGTGTA-3’ 5’-CATGAAAATGGTCAGAGAA-3’ 55 
K-Ras 3 5’-GGTGCACTGTAATAATCCAGA-3’ 5’-TGATTTAGTATTATTTATGGC-3’ 49 
BRAF 15 5’-TCATAATGCTTGCTCTGATAGGA-3’ 5’-GGCCAAAAATTTAATCAGTGGA-3’ 52 
PIK3CA 9 5’-GGGAAAAATATGACAAAGAAAGC-3’ 5’-CTGAGATCAGCCAAATTCAGTT-3’ 56 
PIK3CA 20 5’-CTCAATGATGCTTGGCTCTG-3’ 5’-TGGAATCCAGAGTGAGCTTTC-3’ 55 
TP53 4.1 5’-GAGGACCTGGTCCTCTGACT-3’ 5’-AAGGGACAGAAGATGACAGG-3’ 60 
TP53 4.2 5’-AGAGGCTGCTCCCCGCGTGG-3’ 5’-ATACGGCCAGGCATTGAAGT-3’ 60 
TP53 5 5’-TTCAACTCTGTCTCCTTCCT-3’ 5’-CAGCCCTGTCGTCTCTCCAG-3’ 62 
TP53 6 5’-GCCTCTGATTCCTCACTGAT-3’ 5’-TTAACCCCTCCTCCCAGAGA-3’ 62 
TP53 7 5’-AGGCGCACTGGCCTCATCTT-3’ 5’-TGTGCAGGGTGGCAAGTGGC-3’ 64 
TP53 8 5’-TTCCTTACTGCCTCTTTGCTT-3’ 5’-AAGTGAATCTGAGGCATAAC-3’ 56 
TP53 9 5’-AGCAAGCAGGACAAGAAGCG-3’ 5’-ACTTGATAAGAGGTCCCAAG-3’ 58 
TP53 10 5’-TTTTAACTCAGGTACTGTGT-3’ 5’-CTTTCCAACCTAGGAAGGCA-3’ 58 
 
Table 3.2. Genes analyzed, primers sequences and annealing temperatures.  
 
3.7 MSI 
The status of MSI was assessed by the analysis of the microsatellite loci included in 
the panel of Bethesda (BAT25, BAT26, D2S123, D5S346, and D17S250), as reported in 
the literature (Frattini et al, 2004). The list of primers used for MSI analysis is 
reported in Table 3.3. MSI was confirmed by the presence of additional peak(s) in 
tumor sample compared with the pattern of the normal paired tissue. MSI was 
defined as being present when more than 30% of investigated loci showed instability. 
 
Exon Forward Primer Reverse Primer Annealing  
Temperature (°C) 
BAT25 5’-TCGCCTCCAAGAATGTAAGT-3’ 5’-TCTGCATTTTAACTATGGCTC-3’ 52 
BAT26 5’-TGACTACTTTTGACTTCAGCC-3’ 5’-AACCATTCAACATTTTTAACCC-3’ 52 
D2S123 5’-AAACAGGATGCCTGCCTTTA-3’ 5’-GGACTTTCCACCTATGGGAC-3’ 52 
D5S346 5’-ACTCACTCTAGTGATAAATCGGG-3’ 5’-AGCAGATAAGACAGTATTACTAGTT-3’ 52 
D17S250 5’-GGAAGAATCAAATAGACAAT-3’ 5’-GCTGGCCATATATATATTTAAACC-3’ 52 
 
Table 3.3. Loci analyzed, primers sequences and annealing temperatures. Forward primers 
are labeled with 6-FAM at 5’-end 
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3.8 Allelic imbalance of Chromosome 18q 
Several tumor suppressor genes are located on Chromosome 18. Of these, 3 genes 
play a relevant role in CRC: DCC, SMAD2 (previously named JV18 or MADR2) e 
SMAD4 (previously named DPC4 or MADR4), located on the long arm of 
Chromosome 18 (i.e: q portion of the chromosome). To evaluate if Chromosome 18q 
region is lost, thus meaning that these tumor suppressor genes are absent and 
therefore cannot exert their biologic activity, it is useful to investigate the allelic 
imbalance, also named as loss-of-heterozygosity. 
On the basis of our previous experience (Frattini et al, 2004), we included in our 
analysis the following loci: D18S64, D18S484, D18S474, D18S1110, D18S1161, 
D18S68, D18S1102 (see Figure 3.5 for the location of these loci with respect to DCC, 
SMAD2 and SMAD4 genes).  
 
D18S1110
D18S474 D18S1161D18S64D18S1102
D18S68
CENTROMERO
DCCSMAD4SMAD2
D18S484
 
Figure 3.5. Loci position with respect to the centromere of Chromosome 18q and with respect 
to DCC, SMAD2 and SMAD4 genes. 
 
These loci were analyzed according to the protocol already published (Frattini et al, 
2004). The list of primers used for allelic imbalance of Chromosome 18q is reported in 
Table 3.4. 
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Exon Forward Primer Reverse Primer Annealing  
Temperature (°C) 
D18S64 5’-ATACTGGTGGTGGTTATACAACAT-3’ 5’-AAATCAGGAAATCGGCA-3’ 52 
D18S484 5’-TGTAGCATTTTTAAGACAGTAAAG-3’ 5’-ACATATTCCTTGCTTTGTCA-3’ 52 
D18S474 5’-TGGGGTGTTTACCAGCATC-3’ 5’-TGGCTTTCAATGTCAGAAGG-3’ 52 
D18S1110 5’-TGACCTTGGCTACCTTGC-3’ 5’-TCGAAAGCCTTAAACTCTGA-3’ 52 
D18S1161 5’-GTCCGTCCAACGTCCAA-3’ 5’-GGAGAGCCACACCTATCCTG-3’ 52 
D18S68 5’-ATGGGAGACGTAATACACCC-3’ 5’-ATGCTGCTGGTCTGAGG-3’ 52 
D18S1102 5’-TTTCAGGATTTTGGAGCC-3’ 5’-GGAATGACTGCGTCTGTG-3’ 52 
 
Table 3.4. Loci analyzed, primers sequences and annealing temperatures. Forward primers 
are labeled with 6-FAM at 5’-end. 
 
The analysis requires the availability of healthy tissue. If in the healthy tissue sample 
the 2 alleles have the same size, the patient is homozygous for that locus and cannot 
be evaluated for the analysis of allelic imbalance (the locus is classified as “not 
informative” (NI)).  
If in the tumoral tissue there is the presence of additional peak(s) compared with the 
normal paired tissue, the locus is considered “instable” (or MSI), and again it is 
considered NI for the analysis of allelic imbalance. 
If in both normal and tumoral tissue there are 2 alleles with different sizes, the 
patient is heterozygous for that locus and the allelic imbalance can be ascertained, 
using the following formula: 
 
     N1          T2 
R = -------- x --------- 
     N2          T1 
 
where 
N1 = height of lower dimension peak of healthy tissue 
N2 = height of higher dimension peak of healthy tissue 
T1 = height of lower dimension peak of tumoral tissue 
T2 = height of higher dimension peak of tumoral tissue. 
As cut-off, on the basis of the literature (Frattini et al, 2004), we used the value of 
30%. Therefore, if R is between 0.7 and 1.3, the locus is normal, not lost. If R ≤ 0.70 or 
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R ≥ 1.3, there is allelic imbalance, that means that 1 allele is lost. A patient is classified 
as carrying the loss of the Chromosome 18q region when at least 30% of informative 
loci have R ≤ 0.70 o R ≥ 1.3. 
 
3.9 Statistical analyses 
For all the statistical correlations, we used the Fisher’s exact test because it is 
appropriate for the analysis of small number of cases and for zero values. The level of 
significance was set at p=0.05.  
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RESULTS 
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4.1 Patients cohort 
Between 1996 and 2009, 40 patients affected by SBA were identified in the databases 
of Institute of Pathology of Locarno (Canton Tessin, Southern Switzerland) and in 
those of three institutions of Northern Italy (Departments of Pathology of Legnano, 
Multimedica in Milan, and University of Novara). 
The age at diagnosis was between 41 and 87 years, with a mean age of 66.5 years. 
Men and women were equally distributed (20 cases for both sexes). Tumor location 
included duodenum (35% of cases), jejunum (25% of cases) and ileum (40% of cases). 
Tumor stage was available in 36 cases, because for 4 patients (PT = 9, 12, 15 and 16) 
(Table 4.1) only a biopsy was available. One case (2.5%) was classified as pT1, 2 cases 
(5%) as pT2. Therefore, the vast majority of cases were classified at higher stage, as 
pT3 in 24 cases (60%) and as pT4 in 9 cases (22.5%). 
The majority of cases was classified as G2 (26 cases, 65%), with 9 cases (22.5%) as G3 
and only 3 cases (7.5%) as well differentiated (G1). Two patients (PT = 30 and 31, 
Table 4.1) were G2 with few portions classified as G3 (5%), but were grouped with 
G3 (overall G3: 30% of cases). 
In 4 patients the lymph nodal involvement was not available (Nx). Of the remaining 
36 cases, 15 patients displayed lymph nodal metastasis (pN1).  
As far as metastasization of other organs is concerned, the information was not 
available in 5 cases (pMx). Of the remaining 35 cases, 5 patients displayed a distant 
metastasis at the time of diagnosis of the primary tumor (pM1). 
Of the whole cohort, only 1 case was excluded (PT = 12, Table 4.1) because the DNA 
was not analyzable for both direct sequencing and FISH experiments. We decided 
not to analyze this case also at immunohistochemical level. Therefore, the analyses 
was accomplished on 39 patients. 
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PT id Sex Age at diagnosis Tumor location 
TNM stage 
 (grade) 
1 M 74 Jejunum pT3 pN1 (G3) 
2 M 78 Duodenum pT3 pN0 (G3) 
3 M 57 Ileum pT3 pN0 pM1 (G2) 
4 M 66 Ileum pT4 pN1 (G3) 
5 M 59 Duodenum pT3 pN1 (G2) 
6 F 72 Duodenum pT4 pN0 (G2) 
7 M 87 Duodenum pT1 pNx (G2) 
8 F 74 Duodenum pT4 pN1 (G3) 
9 M 41 Duodenum (G2) 
10 F 76 Ileum pT4 pN1 (G3) 
11 M 78 Jejunum pT3 pN1 (G2) 
12 M 66 Duodenum (G1) 
13 M 65 Duodenum pT3 pN1(G3) 
14 F 61 Duodenum pT4 pN1 (G2) 
15 F 87 Duodenum (G2) 
16 F 81 Duodenum (G3) 
17 M 67 Jejunum pT3 pN0 (G2) 
18 F 59 Jejunum pT3 pN0 (G2) 
19 F 80 Ileum pT4 pN0 pM1 (G2) 
20 F 42 Ileum pT4 pNx pM1 (G2) 
21 M 77 Ileum pT3 pN1 (G2) 
22 M 73 Duodenum pT3 pN0 (G2) 
23 M 71 Ileum pT3 pN0 (G2) 
24 F 63 Ileum pT3 pN0 pMx (G1) 
25 M 73 Duodenum pT3 pN0 (G2) 
26 M 62 Ileum pT4 pN1 (G1) 
27 F 68 Ileum pT3 pNx pMx (G2) 
28 M 62 Ileum pT3 pN0 pMx (G2) 
29 M 67 Duodenum pT4 pN1 pM1 (G2) 
30 F 66 Jejunum pT3 pN1 pM1 (G2-G3) 
31 F 68 Jejunum pT3 pN1 pMx (G2-G3) 
32 F 80 Jejunum pT3 pN0 (G2) 
33 M 48 Jejunum pT3 pNx pMx (G3) 
34 F 69 Jejunum pT3 pN0 (G2) 
35 M 60 Jejunum pT2 pN0 (G2) 
36 F 70 Ileum pT2 pN0 (G2) 
37 F 69 Ileum pT3 pN2 (G2) 
38 F 83 Ileum pT3 pN0 (G2) 
39 F 63 Ileum pT3 pN1 pM1 (G3) 
40 F 73 Ileum pT3 pN1 (G2) 
 
Table  4.1.  Clinico-pathological features of patients affected by SBA and surgically removed 
in Canton Tessin and in Italy (Legnano, Milan and Novara) from 1996 to 2009.  
Legend: F: female; M: male; PT id: patient identification; TNM: Tumor, Node, Metastasis 
system. 
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4.2 β-Catenin protein expression 
Due to lack of material, 1 case was not evaluable (PT = 9). 
Eleven patients displayed a negative expression of β-catenin (an example is reported 
in Figure 4.1), whereas 9 patients (PT = 2, 10, 20, 23, 24, 26, 27, 32 and 36) were 
characterized by a strong protein expression, with a marked immunodecoration not 
only in the cytoplasm but also in the nucleus (Figure 4.2). The remaining 18 patients 
showed β-catenin overexpression, higher than in the healthy mucosa, but only at 
cytoplasmic level (Table 4.2). 
 
PT id β-Catenin  PT id β-Catenin 
1 Pos (cyt)  22 Pos (cyt) 
2 Pos (cyt + nucl)  23 Pos (cyt + nucl) 
3 Pos (cyt)  24 Pos (cyt + nucl) 
4 Neg  25 Pos (cyt) 
5 Neg  26 Pos (cyt + nucl) 
6 Pos (cyt)  27 Pos (cyt + nucl) 
7 Pos (cyt)  28 Pos (cyt) 
8 Neg  29 Pos (cyt) 
10 Pos (cyt + nucl)  30 Neg 
11 Pos (cyt)  31 Pos (cyt) 
13 Neg  32 Pos (cyt + nucl) 
14 Neg  33 Neg 
15 Neg  34 Neg 
16 Pos (cyt)  35 Pos (cyt) 
17 Neg  36 Pos (cyt + nucl) 
18 Pos (cyt)  37 Pos (cyt) 
19 Pos (cyt)  38 Pos (cyt) 
20 Pos (cyt + nucl)  39 Neg 
21 Pos (cyt)  40 Pos (cyt) 
 
Table  4.2.  β-catenin protein expression in evaluable cases, by immunohistochemistry. Cases 
with a strong nuclear expression are labeled in red, those with only cytoplasmic 
overexpression in green. 
Legend: cyt = cytoplasmic expression;  neg = negative expression;  nucl = nuclear expression; 
pos = positive expression; PT id= patient identification.  
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a b
* *


 
Figure 4.1. a: example of negative expression of β-catenin in SBA. b: higher magnification of 
the same region. : normal tissue; *: adenocarcinoma. 
 
a b
*
*


 
Figure 4.2. a: example of strong expression (cytoplasmic and nuclear) of β-catenin in SBA. b: 
higher magnification of the same region. : normal tissue; *: adenocarcinoma. 
 
4.3 Microsatellite instability analysis 
This analysis foresees the amplification of genomic DNA from both tumoral and non 
tumoral portions. For patients with only a biopsy available, normal tissue was 
obtained from another resection, or by microdissection on the same section used for 
DNA extraction of the tumoral portion. Therefore, the analysis of all the loci included 
in the panel of Bethesda was allowed in all the cases. 
Due to lack of material, 1 case was not investigated (PT = 9). 
Twenty-nine cases were characterized by microsatellite stability (MSS). Nine 
patients, on the contrary, were classified as microsatellite instable (MSI).  
Overall, in our cohort of SBA we found 23.6% of cases with MSI feature. 
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PT id Microsatellite status  PT id Microsatellite status 
1 MSI  22 MSS 
2 MSS  23 MSS 
3 MSS  24 MSS 
4 MSS  25 MSS 
5 MSI  26 MSS 
6 MSS  27 MSS 
7 MSS  28 MSI 
8 MSS  29 MSS 
10 MSS  30 MSI 
11 MSS  31 MSS 
13 MSI  32 MSS 
14 MSS  33 MSS 
15 MSI  34 MSI 
16 MSS  35 MSS 
17 MSI  36 MSS 
18 MSS  37 MSS 
19 MSS  38 MSS 
20 MSS  39 MSI 
21 MSS  40 MSS 
 
Table 4.3. Microsatellite instability analysis in SBA evaluable cases. Microsatellite instable 
cases are reported in red. 
Legend: MSI = microsatellite instability; MSS = microsatellite stability; PT id= patient 
identification. 
 
 
4.4 KRAS gene mutations 
KRAS mutational status, performed by direct sequencing of both exons 2 and 3, 
including codons 12, 13 and 61, was performed in 39 cases (Table 4.4). In 22 cases a 
wild-type sequence in both exons was observed. In 17 cases a point mutation was 
identified. More in details, 16 mutations occurred in exon 2 and 1 mutation in exon 3. 
In exon 2, all the mutations were discovered in codon 12: 6 mutations were 
represented by G12D, 3 by G12S, 3 by G12V, 2 by G12C, 1 by G12A e another 1 by 
G12R. As far as exon 3 is concerned, the mutation was identified at codon 61, 
represented by Q61H change (Table 4.4). 
Cumulatively, KRAS mutations are observed in 43.6% of our cohort of SBA. 
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PT id KRAS  PT id KRAS 
1 G12S  22 WT 
2 WT  23 WT 
3 WT  24 WT 
4 WT  25 WT 
5 G12S  26 WT 
6 G12D  27 G12V 
7 WT  28 Q61H 
8 WT  29 WT 
9 WT  30 WT 
10 G12C  31 WT 
11 G12A  32 WT 
13 WT  33 WT 
14 G12R  34 WT 
15 G12V  35 G12D 
16 WT  36 G12S 
17 WT  37 WT 
18 WT  38 G12D 
19 G12D  39 G12D 
20 G12V  40 G12D 
21 G12C    
 
Table 4.4. Mutational status of evaluable cases of KRAS gene (exons 2 and 3), by direct 
sequencing. Cases carrying a mutation are reported in red 
Legend: PT id= patient identification; WT = wild-type. In the mutant cases, numbers identify 
the altered codon, the letter in the left of the number represents the wild-type amino acid 
sequence, the letter in the right of the number represents the altered amino acid. 
 
4.5 Chromosome 18q analysis 
This analysis foresees the amplification of genomic DNA from both tumoral and non 
tumoral portions. For patients with only a biopsy available, normal tissue was 
obtained from another resection, or by microdissection on the same section used for 
DNA extraction of the tumoral portion. 
Three patients were excluded due to lack of material (PT = 9, 16 and 29). Two cases 
were considered to be not evaluable due to the bad quality of genomic DNA, at least 
for the analysis of the long arm of Chromosome 18 (PT = 25 and 37). In addition, the 9 
patients showing MSI at the loci included in the panel of Bethesda, were also 
characterized by microsatellite instability in the loci of Chromosome 18q, and for that 
reason were excluded (Table 4.5). 
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In conclusion, data useful for the characterization of the allelic imbalance of the long 
arm of Chromosome 18 were obtained in 25 cases. Of these, 6 patients did not show 
any loss of the Chromosome 18q region, whereas 19 experienced loss-of-
heterozygosity. 
Therefore, the region including tumor suppressor genes located on Chromosome 18q 
was lost in 76% of SBA. 
 
PT id Chromosome 18q  PT id Chromosome 18q 
1 MSI  21 NL 
2 NL  22 LOH 
3 LOH  23 LOH 
4 NL  24 LOH 
5 MSI  26 LOH 
6 NL  27 LOH 
7 LOH  28 MSI 
8 LOH  30 MSI 
10 LOH  31 LOH 
11 LOH  32 LOH 
13 MSI  33 LOH 
14 NL  34 MSI 
15 MSI  35 LOH 
17 MSI  36 LOH 
18 LOH  38 LOH 
19 NL  39 MSI 
20 LOH  40 LOH 
 
Table 4.5. Chromosome 18q allelic imbalance in SBA evaluable cases. Cases with loss-of-
heterozygosity are reported in red. 
Legend: LOH = loss-of-heterozygosity; MSI = microsatellite instability; NL = non loss; PT id= 
patient identification. 
 
4.6 TP53 gene mutations 
The mutational analysis of TP53 gene was successful in 38 cases, 1 patient (PT = 9) 
was excluded due to lack of material. 
In 27 patients we did not observe any mutation in all the investigated exons, while 11 
patients were characterized by at least one alteration. More in details, 9 patients 
displayed 1 mutation, and 2 patients showed 2 distinct mutations (Table 4.6). 
The mutations identified in patients characterized by 1 mutation were as follows:  
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- Exon 4.2: deletion of 3 nucleotides determining the loss of codon 96 and 
leading therefore to a shorter protein (PT = 30, Table 4.6); 
- Exon 5: missense point mutation leading to the R175H amino acid change (PT 
= 10, Table 4.6) and 2 frameshift alterations (PT = 20 and 33, Table 4.6). The 
frameshift of PT = 20 could not be characterized because the nucleotide 
deletion was too close to the primer sequence. The frameshift alteration of PT 
= 33 was represented by the deletion of nucleotide C in position 459 (located in 
codon 153), leading to an abnormal stop codon at codon 169;  
- Exon 6: non-sense point mutation leading to the stop codon in position 213 (PT 
= 19, Table 4.6); 
- Exon 7: 3 missense point mutations, leading to C242Y aminoacid change in 1 
case (PT = 18, Table 4.6), and to R248W change in 2 cases (PT = 24 and 31, 
Table 4.6);  
- Exon 8: missense point mutation leading to R282W aminoacid change (PT = 32, 
Table 4.6); 
For patients with 2 distinct mutations, we observed the following changes: PT = 2 
(Table 4.6) was characterized by the presence of missense point mutations leading to 
R213Q (exon 5) and G245V (exon 6) amino acid changes; PT = 17 (Table 4.6) was 
characterized by missense point mutations leading to R181C (exon 5) and R273H 
(exon 8) amino acid changes. 
No alterations were identified in exons 9 and 10. 
Cumulatively, 29% of our cohort of SBA displayed at least a TP53 mutation. 
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PT id TP53  PT id TP53 
1 WT  22 WT 
2 R213Q/G245V  23 WT 
3 WT  24 R248W 
4 WT  25 WT 
5 WT  26 WT 
6 WT  27 WT 
7 WT  28 WT 
8 WT  29 WT 
10 R175H  30 FRAMESHIFT 
11 WT  31 R248W 
13 WT  32 R282W 
14 WT  33 FRAMESHIFT 
15 WT  34 WT 
16 WT  35 WT 
17 R181C/R273H  36 WT 
18 C242Y  37 WT 
19 R213STOP  38 WT 
20 FRAMESHIFT  39 WT 
21 WT  40 WT 
 
Table 4.6. Mutational status of SBA evaluable cases of TP53 gene, by direct sequencing. 
Cases carrying a mutation are reported in red 
Legend: PT id = patient identification; WT = wild-type. In the mutant cases, numbers identify 
the altered codon, the letter in the left of the number represents the wild-type amino acid 
sequence, the letter in the right of the number represents the altered amino acid. 
 
 
4.7 EGFR gene status. 
Six patients (PT = casi 7, 13, 23, 25, 29 and 37, Table 4.7) were not evaluable due to 
fixation artifacts or to lack of material.  
Four patients (PT = 1, 9, 17 and 30, Table 4.7) showed a disomic pattern (2n) in more 
than 60% of cells; 2 patients (PT = 15 and 38, Table 4.7) were characterized by LP, that 
means trisomy and/or tetrasomy, in at least 40% of cells; 8 patients showed disomy in 
more than 60% of cells and LP in remaining cells (2n+LP); 13 cases demonstrated HP 
in at least 40% of cells; 4 patients (PT = 18, 27, 32 and 34, Table 4.7) were characterized 
by LP with prevalence of tetrasomy (4n) in at least 40% of cells), 1 patient (PT = 20, 
Table 4.7) showed LP in at least 40% of cells and a little percentage of cells with gene 
amplification (LP+a); and 1 cases (PT = 33, Table 4.7) showed gene amplification (a). 
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Following the criteria described in 3.4.1 section, the 2n, LP (trisomy) and 2n+LP 
(trisomy) groups were classified as FISH negative (FISH-) (Figure 4.3, Table 4.7) 
while HP, LP+a e a groups as FISH positive (FISH+) (Figure 4.4, Table 4.7).  
Overall, 19 out of 33 evaluable cases were considered as FISH+ (57.5%). 
 
PT id Categories Status  PT id Categories status 
1 2n FISH -  21 2n+LP (3n) FISH - 
2 HP FISH +  22 HP FISH + 
3 HP FISH +  24 HP FISH + 
4 2n+LP (3n) FISH -  25 NV NV 
5 2n+LP (3n) FISH -  26 HP FISH + 
6 2n+LP (3n) FISH -  27 4n FISH + 
8 HP FISH +  28 2n+LP (3n) FISH - 
9 2n FISH -  30 2n FISH - 
10 2n+LP (3n) FISH -  31 HP FISH + 
11 HP FISH +  32 4n FISH + 
13 NV NV  33 A FISH + 
14 HP FISH +  34 4n FISH + 
15 LP (3n) FISH -  35 HP FISH + 
16 HP FISH +  36 2n+LP (3n) FISH - 
17 2n FISH -  38 LP (3n) FISH - 
18 4n FISH +  39 2n+LP (3n) FISH - 
19 HP FISH +  40 HP FISH + 
20 LP+a FISH +     
 
Table 4.7. EGFR gene status in SBA evaluable cases. FISH positive cases corresponding to a 
abnormal EGFR gene status are reported in red. 
Legend:  2n = disomy; 3n = trisomy; 4n = tetrasomy; a = gene amplification; FISH- = FISH 
negative; FISH+ = positive; HP = high polysomy; LP = low polysomy; PT = patient 
identification.  
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Figure 4.3. Example of EGFR gene status evaluation by FISH in SBA. a: disomy (2n); b: low 
polysomy (LP, trisomy). Red signals correspond to the EGFR gene;  green signals correspond 
to the centromere of Chromosome 7. 
 
 
a b
 
Figure 4.4. Example of EGFR gene status evaluation by FISH in SBA. a: high polysomy (HP); 
b: gene amplification. Red signals correspond to the EGFR gene;  green signals correspond to 
the centromere of Chromosome 7. 
 
4.8 BRAF gene mutations 
BRAF mutations were investigated in exon 15 in 39 patients. Thirty-eight cases 
showed a wild-type sequence. One patient (PT = 18, Table 4.8) displayed a missense 
point mutation, leading to the G596R amino acid change. This patient was also 
characterized by MSS in the loci of the Bethesda panel (Table 4.3) and by absence of 
KRAS mutations (Table 4.4). No BRAF V600E mutations were observed. No BRAF 
mutations were observed in MSI cases.  
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Overall, BRAF mutations were identified in 2.6% of our SBA. 
 
PT id BRAF  PT id BRAF 
1 WT  22 WT 
2 WT  23 WT 
3 WT  24 WT 
4 WT  25 WT 
5 WT  26 WT 
6 WT  27 WT 
7 WT  28 WT 
8 WT  29 WT 
9 WT  30 WT 
10 WT  31 WT 
11 WT  32 WT 
13 WT  33 WT 
14 WT  34 WT 
15 WT  35 WT 
16 WT  36 WT 
17 WT  37 WT 
18 G596R  38 WT 
19 WT  39 WT 
20 WT  40 WT 
21 WT    
 
Table 4.8. Mutational status of SBA evaluable cases of BRAF gene (exon 15), by direct 
sequencing. Cases carrying a mutation are reported in red 
Legend: PT id = patient identification; WT = wild-type. In the mutant cases, numbers identify 
the altered codon, the letter in the left of the number represents the wild-type amino acid 
sequence, the letter in the right of the number represents the altered amino acid. 
 
4.9 PIK3CA gene mutations 
PIK3CA mutations were investigated in exons 9 and 20 in 39 patients. Thirty-five 
cases showed a wild-type sequence (Table 4.9). 
Four patients showed PIK3CA mutations, in particular:  
- Exon 9: 2 missense point mutations, leading to E542K aminoacid change in 1 
case (PT = 10, Table 4.9), and to Q546P change in 1 case (PT = 21, Table 4.9);  
- Exon 20: 2 missense point mutations, leading to H1047R aminoacid change in 
1 case (PT = 19, Table 4.9), and to G1049S change in 1 case (PT = 11, Table 4.9);  
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No mutations were found at codon 545 of exon 9, which represents the most altered 
codon in that exon. 
Overall, PIK3CA mutations were identified in 10.2% of our cohort of SBA. 
 
PT id PIK3CA  PT id PIK3CA 
1 WT  22 WT 
2 WT  23 WT 
3 WT  24 WT 
4 WT  25 WT 
5 WT  26 WT 
6 WT  27 WT 
7 WT  28 WT 
8 WT  29 WT 
9 WT  30 WT 
10 E542K  31 WT 
11 G1049S  32 WT 
13 WT  33 WT 
14 WT  34 WT 
15 WT  35 WT 
16 WT  36 WT 
17 WT  37 WT 
18 WT  38 WT 
19 H1047R  39 WT 
20 WT  40 WT 
21 Q546P    
 
Table 4.9. Mutational status of SBA evaluable cases of PIK3CA gene (exons 9 and 20), by 
direct sequencing. Cases carrying a mutation are reported in red. 
Legend: PT id = patient identification; WT = wild-type. In the mutant cases, numbers identify 
the altered codon, the letter in the left of the number represents the wild-type amino acid 
sequence, the letter in the right of the number represents the altered amino acid. 
 
4.10 PTEN protein expression 
The immunohistochemical evaluation of PTEN protein was performed in 39 cases 
(Table 4.10). Twenty-nine patients showed a PTEN expression similar to that 
observed in normal healthy mucosa (PTEN positive) (Figure 4.5), while 10 patients 
(PT = 3, 9, 14, 15, 16, 17, 18, 29, 34 and 38, Table 4.10) showed a loss of PTEN protein 
expression (i.e.: negative expression). 
Overall, 25.6% of SBA showed loss of PTEN protein expression. 
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PT id PTEN  PT id PTEN 
1 Pos  22 Pos 
2 Pos  23 Pos 
3 Neg  24 Pos 
4 Pos   25 Pos 
5 Pos  26 Pos 
6 Pos  27 Pos 
7 Pos  28 Pos 
8 Pos  29 Neg 
9 Neg  30 Pos 
10 Pos  31 Pos 
11 Pos  32 Pos 
13 Pos  33 Pos 
14 Neg  34 Neg 
15 Neg  35 Pos 
16 Neg  36 Pos 
17 Neg  37 Pos 
18 Neg  38 Neg 
19 Pos  39 Pos 
20 Pos  40 Pos 
21 Pos    
 
Table 4.10. PTEN protein expression in SBA evaluable cases, by immunohistochemistry. 
Negative cases corresponding to an abnormal protein expression are reported in red. 
Legend: Neg = negative (abnormal expression); Pos = positive (normal expression) PT id = 
patient identification; WT = wild-type.  
 
 
 
Figure 4.19. Example of normal expression of PTEN protein in SBA. 
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Figure 4.20. Example of loss of PTEN protein expression in SBA. 
 
4.11 Correlations 
By matching clinico-pathological and immunohistochemical-cytogenetic-molecular 
data, we observed several interesting correlations in our cohort of SBA. 
-  When we matched the single clinico-pathological parameters (sex, age at 
diagnosis, tumor location, tumor stage, tumor grade) with all the molecular 
alterations investigated (KRAS, TP53, BRAF and PIK3CA gene mutations, 
allelic imbalance of Chromosome 18q, MSI, β−catenin and PTEN protein 
expression, EGFR gene status) we found a significant correlation between 
TP53 mutational status and tumor location. In fact, TP53 mutations occurred 
more frequently in tumors arising in the jejunum than in those of the 
duodenum or ileum (p=0.02) (Tables 4.11 and 4.12). All the other correlations 
were not statistically significant. 
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  SEX  p  AGE  p  LOCATION  p 
  M F     ≤ 60 > 60     Jejunum Ileum Duodenum    
                 
KRAS WT 13 9   4 18   7 6 8  
 Mut 6 11  
0,2 
 3 14  
1 
 3 10 5  
0,24 
                
TP53 WT 16 12   4 24   4 12 12  
 Mut 3 8  
0,155 
 3 8  
0,37 
 6 4 1  
0,02 
                
Microsatellite MSI 13 16   5 24   6 14 9  
 MSS 5 4  
0,708 
 1 8  
0,9 
 4 2 3  
0,31 
                
Chr 18q L 7 12   5 14   6 10 3  
 NL 4 2  
0,35 
 0 6  
0,2 
 0 3 3  
0,15 
                 
BRAF WT 19 19   6 32   9 16 13  
 Mut 0 1  
1 
 1 0  
0,17 
 1 0 0  
0,26 
                 
PIK3CA WT 17 15   6 28   8 13 13  
 Mut 2 4  
0,66 
 0 4  
1 
 2 3 0  
0,28 
                 
PTEN Pos 15 13   5 24   7 14 8  
 Neg 4 6  
1,714 
 2 8  
0,9 
 3 2 5  
0,26 
                 
β-Catenin Pos C 10 8   3 15   5 7 6  
 Pos N 4 6   1 8   1 7 1  
 Neg 6 5  
0,7 
 2 9  
0,99 
 4 2 5  
0,14 
                 
EGFR Pos 7 12   11 8   7 7 5  
 Neg 5 7  
1 
 7 7  
0,732 
 3 7 4  
0,609 
 
 
Table 4.11. Correlations among clinico-pathological features and immunohistochemical-
cytogenetic-molecular data in SBA. p values are calculated using the two-tailed Fisher’s exact 
test. Significant correlations (p < 0.05) are reported in red. 
Legend: C = cytoplasm; Chr = chromosome; L = loss-of-heterozygosity; Mut = mutated; N = 
nucleus; Neg = negative; NL = non loss (absence of loss-of-heterozygosity); Pos = positive; 
WT = wild-type.  
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 STAGE 
 
  GRADE 
 
 
  
 T1 T2 T3 T4 
 
p   N0 N1-N2 M1 
 
P 
 
G1 G2 G3 
 
p 
  
 
                  
KRAS WT  1 0 15 4   10 7 1   2 12 8  
 Mut  0 2 8 5  
0,2 
 5 7 2  
0,5 
 1 13 2  
0,28 
                     
TP53 WT  1 2 14 6   9 10 2   2 17 5  
 Mut  0 0 8 3  
0,9 
 6 3 2  
0,5 
 1 5 5  
0,28 
                     
Microsatellite MSI  1 2 15 9   12 11 3   3 20 7  
 MSS  0 0 8 0  
0,2 
 3 4 1  
0,9 
 0 5 3  
0,69 
                     
Chr 18q L  1 2 10 5   8 6 2   3 12 4  
 NL  0 0 13 4  
0,2 
 7 9 2  
0,8 
 0 13 6  
0,2 
                     
BRAF WT  1 2 22 9   14 15 4   3 24 10  
 Mut  0 0 1 0  
1 
 0 0 1  
0,14 
 0 1 0  
1 
                     
PIK3CA WT  1 2 20 7   14 11 3   2 23 8  
 Mut  0 0 3 2  
0,8 
 1 4 1  
0,34 
 1 2 2  
0,29 
                     
PTEN Pos  1 2 20 6   12 12 3   3 17 8  
 Neg  0 0 3 3  
0,5 
 3 3 1  
0,99 
 0 8 2  
0,6 
                     
β-Catenin Pos C  1 1 11 3  
 
 8 7 2   1 14 3  
 Pos N  0 1 5 3  0,79  5 2 2   2 5 2  
 Neg  0 0 7 3  
 
 2 7 1  
0.29 
 0 5 5  
0,17 
                     
EGFR Pos  0 1 12 5   9 6 2   2 11 5  
 Neg  0 1 7 3  
1 
 4 6 2  
0,58 
 0 12 4  
0,6 
 
 
Table 4.12. Correlations among clinico-pathological features and immunohistochemical-
cytogenetic-molecular data in SBA. p values are calculated using the two-tailed Fisher’s exact 
test. Significance is set up at p < 0.05. 
Legend: C = cytoplasm; Chr = chromosome; L = loss of heterozygosity; Mut = mutated; N = 
nucleus; Neg = negative; NL = non loss (absence of loss of heterozygosity); Pos = positive; 
WT = wild-type.  
 
- Then, by correlating β−catenin protein expression with MSI (representing the 
two different models of colorectal carcinogenesis), we found that this 
association was statistically significant. In fact, patients with MSI were 
characterized by absence of β−catenin overexpression (p=0.001) (Table 4.13).  
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  β-Catenin  p 
  
 Pos C Pos N Neg    
  
      
Microsatellite MSS  16 9 4  
 MSI  2 0 7  
0,01 
 
Table 4.13. Correlation between β-catenin protein expression and microsatellite instability in 
SBA. p values are calculated using the two-tailed Fisher’s exact test. Significant correlation (p 
< 0.05) are reported in red. 
Legend: C = cytoplasm; MSI = microsatellite instability; MSS = microsatellite stability; N = 
nucleus; Neg = negative; Pos = positive.  
 
 
- Then, we compared the EGFR gene status with all the other molecular 
alterations and we found a statistically significant association between FISH 
positivity and the status of microsatellite loci included in the panel of 
Bethesda. In fact, a FISH positive pattern was more frequently found in MSS 
patients (p=0.004) (Table 4.14). In addition, we observed trends (but not 
statistically significant) between FISH positivity and the loss of heterozigosity 
(L) of Chromosome 18q (the majority of patients with Chromosome 18q loss 
are FISH positive for EGFR) (p=0.08) or with KRAS mutations (the majority of 
KRAS mutant cases are FISH positive for EGFR) (p=0.079) (Table 4.14). 
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   EGFR  p 
   Pos Neg   
       
KRAS WT  12 4  
 Mut  7 10  
0,079 
       
TP53 WT  11 11  
 Mut  8 3  
0,28 
       
Microsatellite MSS  18 7  
 MSI  1 7  
0,004 
       
Chr 18q L  15 3  
 NL  2 3  
0.08 
       
BRAF WT  18 14  
 Mut  1 0  
1 
       
PIK3CA WT  16 12  
 Mut  3 2  
1 
       
PTEN Pos  15 9  
 Neg  4 5  
0,44 
       
β-Catenin Pos C  9 5  
 Pos N  6 2  
 Neg  4 6  
0,3 
 
Table 4.14. Correlation among EGFR gene status by FISH and immunohistochemical-
molecular data in SBA. p values are calculated using the two-tailed Fisher’s exact test. 
Significant correlations (p < 0.05) are reported in red. 
Legend: C = cytoplasm; Chr = chromosome; L = loss of heterozygosity; Mut = mutated; N = 
nucleus; Neg = negative; NL = non loss (absence of loss of heterozygosity); Pos = positive; 
WT = wild-type.  
 
- Finally, we stratified the patients on the basis of the molecular alterations 
involved in colorectal carcinogenetic models (KRAS and TP53 mutations, 
allelic imbalance of Chromosome 18q) in MSS cases (because MSI cases follow 
a different mechanism of cancerogenesis). In this subgroup of 25 patients, 36% 
of cases was characterized by alteration of a single marker (KRAS mutations in 
3 cases, 12%; TP53 mutations in 1 case, 4%; Chromosome 18q loss in 5 cases, 
20%). Twenty percent of patients showed alterations of both TP53 and 
Chromosome 18q (5 cases), whereas 24% of patients both at KRAS and 
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Chromosome 18q level (6 cases). All the 3 molecular alterations were observed 
in 3 cases (12%). In our cohort of SBA, the concomitant alteration of KRAS and 
TP53 was not identified. Finally, 8% of patients carried none of the three 
molecular alterations taken into account for this analysis (Figure 4.21). 
 
MSS-K-Ras ; 12%
MSS-Cr18q; 20%
MSS-TP53; 4%
MSS-K-Ras+Cr18q; 
24%
MSS-TP53+Cr18q; 
20%
MSS-Ras 
+TP53+Cr18q; 12%
No alterations; 8%
 
Figure 4.21. Subgroup of patients on the basis of KRAS mutations, allelic imbalance of 
Chromosome 18q and TP53 mutations in SBA cases characterized by MSS. 
Legend:  Chr18q: Chromosome 18q. 
 
By comparing these subgroups with tumor stage, we observed that the 2 
metastatic cases with MSS feature were characterized by the simultaneous 
occurrence of KRAS and TP53 mutations, and by Chromosome 18q loss. In 
addition, all the 3 cases showing the concomitant alteration of the 3 markers 
were classified at pT4 stage. 
 
- When we compared the alterations occurring in EGFR downstream pathways 
(KRAS, BRAF and PIK3CA mutations, and PTEN protein expression) in 
patients characterized by a copy number gain of EGFR gene (i.e.: FISH 
positive cases) (19 patients), in 10 cases we observed at least 1 alteration in 
EGFR downstream members (4 with alteration at KRAS level, 2 with PTEN 
negative expression, 2 with mutations in both KRAS and PIK3CA genes, 1 with 
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KRAS mutation and PTEN loss of expression, 1 with BRAF mutation and 
PTEN loss of expression) (Table 4.15). Therefore, 9 patients were characterized 
by an alteration of the EGFR pathway limited to a copy number gain of EGFR, 
and absence of any other alteration in EGFR downstream pathways.   
 
PT id EGFR K-Ras BRAF PIK3CA PTEN 
2 FISH + WT WT WT pos 
3 FISH + WT WT WT pos 
8 FISH + WT WT WT pos 
11 FISH + G12A WT G1049S pos 
14 FISH + G12R WT WT neg 
16 FISH + WT WT WT neg 
18 FISH + WT G596R WT neg 
19 FISH + G12D WT H1047R pos 
20 FISH + G12V WT WT pos 
22 FISH + WT WT WT pos 
24 FISH + WT WT WT pos 
26 FISH + WT WT WT pos 
27 FISH + G12V WT WT pos 
31 FISH + WT WT WT pos 
32 FISH + WT WT WT pos 
33 FISH + WT WT WT pos 
34 FISH + WT WT WT neg 
35 FISH + G12D WT WT pos 
40 FISH + G12D WT WT pos 
 
Table 4.15. Cumulative analysis of EGFR pathways in EGFR FISH positive cases of SBA. 
Cases carrying an alteration in EGFR downstream pathways are reported in red. 
Legend: neg = negative; pos = positive; PT id = patient identification; WT = wild-type. In the 
mutant cases, numbers identify the altered codon, the letter in the left of the number 
represents the wild-type amino acid sequence, the letter in the right of the number represents 
the altered amino acid. 
 
4.12 Correlation of molecular data with clinical response to EGFR-targeted therapy 
Patient #3 (Table 4.1) developed an aggressive disease and was addressed to the 
administration of EGFR-targeted therapies. More in details, when he was 48, the 
patient complained of abdominal pain and vomiting referable to intestinal 
obstruction. An abdominal CT scan showed multiple liver metastasis and peritoneal 
carcinomatosis. The explorative laparotomy revealed a tumor mass of the ileum 
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consistent with an adenocarcinoma, and a palliative resection was performed. So the 
distant (and very spread) metastatic lesions were synchronous with the discovery of 
the primary tumor. Chemotherapy with oxaliplatin and capecitabine was 
administered for 10 months, and a PR was achieved as best response. Due to PD, the 
FOLFIRI regimen was prescribed for 8 months, and a PR was obtained. Then the 
patient experienced weight loss, abdominal pain and subocclusive bowel episodes 
due to progression of abdominal metastatic sites. Based on good performance status 
(PS), disabling tumor-related symptoms and absence of standard therapeutic options, 
the molecular characterization of the EGFR pathway was performed. The patient 
turned out to show EGFR copy number gain (FISH positive) and absence of any 
alterations in EGFR downstream pathways (i.e.: KRAS wild-type, BRAF wild-type, 
PIK3CA wild-type, and PTEN positive expression). After informed consent, 
cetuximab was administered in combination with irinotecan. The treatment was 
relatively well tolerated, and only a grade 2 cutaneous rash developed. After 8 
weeks, the CT scan documented a disease stabilization, with a rapid and dramatic 
relief of symptoms (pain improvement according to the Visual Analogue Scale and 
reduced analgesic consumption). Unfortunately, after 5 months of therapy, the 
patient experienced obstructive abdominal symptoms with deterioration of PS. 
Consequently he was referred to best supportive care, and death occurred due to PD. 
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DISCUSSION 
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SBA is a rare but aggressive disease. Due to its rarity, only few studies have 
investigated this neoplastic disease, and several aspects still need to be elucidated: 
for example, it is not known if patients characterized by a tumor with regional lymph 
nodes invaded by metastatic cells, has a worse prognosis than patients without 
metastatic disease. Risk factors and histological appearance of SBA are 
superimposable with those of colorectal cancers (Delaunoit et al, 2004; Pan et al, 
2011). This finding has led clinicians to the treatment of SBA patients with protocols 
set-up for colorectal adenocarcinomas. 
At molecular level, at odds with colorectal cancer which has been the object of 
extensive investigation, SBA is very poorly characterized. For colorectal cancers, two 
models of cancerogenesis have been proposed: the first one is characterized by MSI 
and is valid for a subgroup (10-15% of cases) of sporadic cases as well as for patients 
belonging to HNPCC families (Ilyas et al, 1999; Houlston et al, 2001); the second one 
is characterized by the sequential occurrence of alterations in APC, KRAS, tumor 
suppressor genes located on the long arm of Chromosome 18q, and TP53, and is 
valid for the vast majority of sporadic cases as well as for patients belonging to FAP 
families (Laurent-Puig et al, 1999; Fearon and Vogelstein, 1990). 
Very few studies have investigated SBA at molecular level. Generally the markers 
involved in the two models proposed for colorectal carcinogenesis have been studied 
in SBA, but not in an organic way. Indeed, the studies published so far investigated 
only few markers. Despite these limitations, on the basis of the similar percentages of 
alterations of the aforementioned markers observed in SBA with respect to colorectal 
cancer, it has been proposed that the models of carcinogenesis proposed for 
colorectal cancer are valid for SBA too. 
To demonstrate in a clearer manner if the assumption that SBA carcinogenesis is 
superimposable with that of colorectal cancer (thus better justifying that SBA patients 
can be treated with chemotherapies set-up and validated for colorectal cancer 
patients), we decided to investigate all the aforementioned markers in the same 
cohort of SBA. To do this we recruited tissues from different institutions: the Institute 
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of Pathology in Locarno and 3 institutions from Northern Italy. We excluded cases 
for which the duodenal origin was doubtful (i.e.: cases in which the tumor was 
diffused also in the pancreas and the histological analysis showed a poorly 
differentiated aspect) and tumors of the papilla of Vater, in order to have an 
homogeneous cohort (cases of Papilla of Vater have pancreatic features and the 
percentage of KRAS mutations is increased with respect to SBA). Our cohort had 
clinical characteristics similar to those observed in the studies already published, 
with a little prevalence of tumors arising in the ileum (40%) with respect to those 
occurred in the duodenum (35%). More than 80% of cases were at advanced stage 
(60% pT3 and 22.5% pT4), and about half of patients displayed the presence of 
metastatic cells at least in regional lymph nodes (41.6%). 
Percentages and type of alterations in our cohort were superimposable with those 
reported in the literature concerning SBA studies 
(http://www.sanger.ac.uk/genetics/CGP/cosmic; Bläker et al, 2002; Planck et al 2003; 
Delaunoit et al, 2005; Overman et al, 2010). 
When we matched the results obtained in our cohort of SBA with those published in 
colorectal cancer (and also with unpublished results on colorectal cancer obtained in 
our laboratory), we observed a quite high rate of MSI (23.6% of cases). Usually, in 
colorectal cancer the percentage of MSI cases is around 10-15%, but there are also 
some cohorts with a rate of MSI higher than that range (Bläker et al, 2002; Markowitz 
and Bertagnolli, 2009), so we can conclude that a superimposable number of SBA and 
colorectal cancer follow the MSI-based model of cancerogenesis. 
As for the analysis of the APC-β-catenin pathway alterations, we focused our 
attention on the evaluation of β-catenin protein expression. Deregulation of the APC-
β-catenin pathway (due to either APC mutations, or APC loss-of-heterozigosity, or 
APC promoter hypermethylation, or β-catenin mutations) leads, in fact, to β-catenin 
accumulation, mainly in the nucleus but also in the cytoplasm, detectable by an 
increase of β-catenin expression in IHC. In our cohort of SBA, only 23.6% of cases 
showed β-catenin expression at nuclear level, and additional 47.3% showed β-catenin 
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overexpression only at cytoplasmic level, thus confirming a previous report 
(Overman et al, 2010). However, we should note that if APC mutations are detected 
in the vast majority of cases of colorectal cancer (more than 80% of sporadic cases), 
the reported rates for β-catenin expression in colorectal cancer range from 20 to 
100%, thus showing that there is not 100% concordance between altered levels of β-
catenin expression and APC alterations. This fact could be due to the difficulties in 
the evaluation of this marker. The results of our cohort, therefore, are consistent with 
those of colorectal cancer (Frattini et al, 2004). Additionally, by comparing 
microsatellite status and β-catenin expression, we found that the two alterations, 
which are alternatively altered in colorectal cancer, are significantly associated with 
different mechanisms of cancerogenesis also in SBA. 
As for KRAS, we found a point mutations in about 40% of cases, mainly at codon 12. 
The percentage and the types of alterations in codons 12 and 61 mirror those 
reported for colorectal cancer (Markowitz and Bertagnolli, 2009). However, in 
colorectal cancer, a not negligible fraction of cases (about 20% of those carrying a 
KRAS mutation) show a mutation at codon 13 (the G13D change in nearly the totality 
of cases). This datum is discrepant with our cohort of SBA, where no cases with 
KRAS codon 13 mutations were observed. A possible explanation of this finding is as 
follow. Although the prognostic role of KRAS mutations has never been confirmed, it 
has been proposed that specific mutations might be associated with different tumor 
behaviour. Finkelstein and colleagues, two decades ago, proposed in particular that 
codon 13 mutations might be associated with an indolent phenotype of the tumor, 
whereas mutations occurring at codon 12 might be associated with a more aggressive 
disease (Finkelstein et al, 1993). This hypothesis was sustained by a recent work of 
Zlobec and colleagues, who demonstrated that patients with KRAS codon 13 
mutations experience a better prognosis than those with a KRAS codon 12 alteration 
(Zlobec et al, 2010). Ninety percent of our cohort of SBA was represented by T3/T4 
stage tumors, a datum which can indirectly justify the absence of KRAS codon 13 
mutations in our cohort of SBA. 
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As regards the allelic imbalance of Chromosome 18q, the percentage of deregulation 
found in the cohort of SBA is in the range observed in colorectal cancer (Markowitz 
and Bertagnolli, 2009). The same is true also for TP53 mutations (for both percentage 
of alterations and types of mutations), although the percentage of mutations in our 
cohort of SBA is quite low, but still in the range of colorectal cancer (Markowitz and 
Bertagnolli, 2009).  
Focusing the attention on MSS cases where the analyses of allelic imbalance of 
Chromosome 18q could be performed, and excluding β-catenin expression (in 
agreement with a similar work appeared on colorectal cancer) (Frattini et al, 2004), 
we observed the following patterns of molecular alterations: 
- 8% of cases: no alterations found; 
- 36% of cases: only 1 alteration (KRAS: 12%, Chromosome 18q: 20%; TP53: 4%); 
- 44% of cases: 2 alterations (Chromosome 18q+TP53: 20%; KRAS+TP53: 24%); 
- 12% of cases: 3 alterations (KRAS+Chromosome 18q+TP53). 
These combinations of alterations are superimposable with those obtained by the 
analysis of a cohort of colorectal cancer (Frattini et al, 2004). It is noteworthy that all 
the 3 cases with 3 alterations (KRAS+Chromosome 18q+TP53) were classified as T4 
and, in 2 cases, a distant metastatic lesion was also present at the time of first 
diagnosis, thus confirming the association between the accumulation of genetic 
alterations in the markers involved in the Vogelstein’s models, with tumor 
progression and, in particular, with late stages of carcinogenesis. 
In conclusion, the analyses of the markers playing a pivotal role in the two 
carcinogenetic models proposed by Vogelstein’s group in colorectal cancer, indicate a 
superimposable pattern of alteration (both for percentages and types of mutations) 
between SBA and colorectal cancer. Our data reinforce therefore the choice of 
oncologists to treat SBA patients with protocols valid for adenocarcinoma of the large 
intestine. 
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In colorectal cancer, the analysis of all the aforementioned markers have not been 
introduced in clinical practice (excluding MSI, used in diagnosis for the identification 
of patients belonging to HNPCC families), whereas a new pathway, the EGFR 
pathway, has acquired high clinical relevance. Therefore, the demonstration that SBA 
and colorectal cancer share the same molecular alterations and the same 
cancerogenetic development, led us to investigate the EGFR pathway in SBA, with 
the goal of the introduction of new therapies in SBA management. In colorectal 
cancer, in fact, EGFR-targeted therapies represent a success story, because metastatic 
patients treated with these compounds experienced longer overall survival with 
respect to patients treated with classical chemotherapies only. However, it has been 
demonstrated that only a subgroup of patients may be sensitive to these therapies, 
and that a careful molecular evaluation of patient’s tumors may predict the efficacy 
of EGFR-targeted therapies. 
In the literature, Overman and colleagues demonstrated EGFR overexpression at 
protein level in 70% of SBA (Overman et al, 2010), a percentage in keeping with 
colorectal cancer data. However, in adenocarcinoma of the large intestine it has been 
shown that immunohistochemistry is not a gold standard method to evaluate EGFR, 
because the type of fixative used, the storage time of unstained tissue sections 
(Atkins et al, 2004), the type of primary antibody used (Kersting et al, 2006) and the 
methods of IHC evaluation (Langner et al, 2004) might generate conflicting data in 
the EGFR assessment.  
However, it has been proposed that EGFR gene copy number gain (analyzed by 
FISH) may represent an efficient marker to identify patients who can benefit from 
EGFR-targeted therapies administration (Moroni et al, 2005; Lièvre et al, 2006, 
Frattini et al, 2007; Sartore-Bianchi et al, 2007; Cappuzzo et al, 2008). In our cohort of 
SBA, an EGFR gene copy number gain was observed in 57.5% of cases, a percentage 
in keeping with the literature of colorectal cancer (Frattini et al, 2007; Martin et al, 
2009). This group may therefore include the patients to be addressed to the 
administration of EGFR-targeted therapies. However, a recent ring test among 
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several laboratories with high experience in EGFR FISH evaluation, has 
demonstrated that such a methodology suffers from inter-observer variability 
(Sartore-Bianchi et al, 2012), preventing, therefore, the use of such a marker for the 
selection of patients to be addressed to EGFR MoAb administration. 
A well accepted marker useful for early identification of the efficacy of EGFR-
targeted therapies is represented by the occurrence of KRAS mutations (Custodio et 
al, 2013). In particular, FDA and EMA guidelines indicate that only patients with a 
KRAS wild-type sequence can be addressed to EGFR MoAb treatment. With this 
simple and fast test, about 30-40% of cases who are naturally resistant to anti-EGFR 
compounds (due to the presence of KRAS mutation) can be excluded from the 
administration of such therapies and addressed to more appropriate 
chemotherapeutic combinations. As for BRAF, PIK3CA and PTEN deregulations, 
however, the information on the effect of these alterations on the efficacy of EGFR-
targeted therapies in advanced colorectal cancer patients are not completely 
confirmed. The majority of studies (reviewed by Custodio et al, 2013) indicate that 
the BRAF V600E change, as well as PIK3CA exon 20 mutations and the loss of 
expression of PTEN may represent alternative negative predictors of the efficacy of 
EGFR-targeted therapies. However these tests have not entered in clinical practice, 
even if it was reported that the combination of all these analyses may increase the 
possibility to early identify patients resistant to EGFR MoAbs (Frattini et al, 2007; 
Sartore-Bianchi et al, 2010). Overall, in our cohort of SBA, if we look only at KRAS 
mutations, we can propose the administration of EGFR-targeted therapies to about 
60% of patients (i.e.: only on KRAS wild-type cases), and to 23% of cases if we base 
our evaluation on the whole EGFR pathway (i.e.: only on cases showing, at the same, 
time, EGFR copy number gain, BRAF and PIK3CA wild-type sequence, and PTEN 
normal expression). However, as for colorectal cancer, these hypotheses must be 
confirmed at clinical level, with ad hoc clinical trials where the molecular 
characterization is performed on treated patients. 
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Although these data are missing for SBA, at the moment, oncologists at the Oncology 
Institute of Southern Switzerland (Bellinzona), starting from the similarity at 
molecular level of SBA and CRC, decided to treat a SBA patient with advanced 
disease with EGFR-targeted therapies (i.e.: cetuximab). Our case was the first report 
of the use of an anti-EGFR MoAb in combination with chemotherapy in advanced 
SBA. After adding cetuximab to irinotecan as third line regimen, the patient 
experienced disease stabilization with translated clinical benefit. At molecular level, 
the patient showed EGFR gene copy number gain and absence of any alterations in 
EGFR downstream pathways (in particular, the KRAS gene was wild type for codons 
12, 13 and 61). This finding, although anecdotic, confirm in SBA the results obtained 
by our laboratory in colorectal cancer patients treated with EGFR-targeted therapies 
(Frattini et al, 2007; Di Nicolantonio et al, 2008; Sartore-Bianchi et al, 2009) and 
reinforce the notion that  a better understanding of molecular alterations 
characterizing SBA is mandatory to early identify patients to be addressed to EGFR 
MoAb. Our work was then supported by another study, where it has been reported 
reported 4 SBA patients treated with cetuximab, all showing disease stabilization, or 
partial or complete response (Santini et al, 2010). In three of these cases the KRAS 
gene status was investigated, and in all the cases the Authors did not find any KRAS 
mutation, thus confirming the negative predictive role of KRAS mutations in EGFR-
targeted therapies, not only in colorectal cancer but also in SBA.  
Finally, it should be mentioned that new markers playing a predictive role of the 
efficacy if EGFR MoAb have been recently introduced into clinical practice. These 
additional alterations are KRAS mutations not occurring at codons 12 and 13 (i.e.: at 
codons 59, 61, 117 and 146) and NRAS mutations. These markers have been 
approved by FDA only few months ago, and were not tested in our cohort of SBA. 
However, our work on SBA tumors will be followed by the extensive 
characterization with next generation sequencing technology (i.e.: Ion Torrent), using 
the Hot Spot Cancer Panel, which includes more than 700 mutations in 50 genes, and 
all KRAS and all NRAS mutations are included. The analyses are now on going.  
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By the analysis of EGFR pathway, we can observe four corollaries: 
- the first one is represented by the correlations between EGFR gene status and 
the other molecular alterations. In our cohort of SBA, we found that EGFR gene 
copy number was associated with a MSS pattern and with loss-of-heterozigosity 
of Chromosome 18q. Since in colorectal cancer MSS and allelic imbalance of 
Chrsomome 18q are associated with worse prognosis, we can suggest that EGFR 
gene copy number gain may be associated with a more aggressive disease also 
in SBA.  
- The BRAF mutation we observed (G596R) is very rare, reported only in few 
cases of colorectal cancer. In addition, it is interesting to note that we did not 
identify any V600E change, the typical BRAF mutation in colorectal cancer, 
especially in MSI cases. Our work is the first investigating BRAF in a SBA 
cohort, and therefore our data deserve confirmation. We can state that the type 
of BRAF mutation in SBA is different than those routinely observed in colorectal 
cancer. 
- The third one is the confirmation also in SBA cases of the mutual exclusivity of 
KRAS and BRAF mutations, already reported for papillary thyroid carcinoma 
(Frattini et al, 2004) in addition to colorectal cancer (Rajagopalan et al, 2002; 
Lièvre et al, 2006; Di Nicolantonio et al, 2008), thus supporting the notion that 
these two genes play a superimposable role in cancer development. 
- The last one is represented by the observation of the mutual exclusivity of 
PIK3CA mutations and PTEN loss of expression, already reported in colorectal 
(Frattini et al, 2005) and in breast carcinoma (Maurer et al, 2009). As for BRAF 
and KRAS, we can therefore hypothesize a superimposable role of PIK3CA and 
PTEN in cancer development 
 
In conclusion, our analysis of SBA confirm the feeling that the mechanisms of 
carcinogenesis of such disease are superimposable with those proposed for colorectal 
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cancer. Therefore the hypothesis that therapeutic protocols valid for the large 
intestine can be applied also to SBA patients is supported. As a consequence, the 
targeted therapies recently introduced in colorectal cancer can be proposed also for 
SBA patients. On this regard, by reporting a case report, we strongly suggest a 
possible role of cetuximab in the management of SBA. Nonetheless, prospective 
controlled trials to ascertain the role of anti-EGFR MoAbs in SBA are warranted. 
Finally, the application in the near future of next generation sequencing technology 
will significantly increase the molecular knowledge of SBA and, possibly, will 
identify new alterations in markers potentially druggable by new targeted therapies. 
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